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ABSTRACT 
     Infectious cDNA clones of PRRSV make it possible to construct marker viruses for the study 
of virus replication and pathogenesis. The nonstructural protein 2 (nsp2) of porcine reproductive 
and respiratory syndrome virus (PRRSV) is the single largest protein produced during virus 
replication. The cDNA of the pCMV-129 infectious PRRSV clone was modified by creating 
unique Mlu I and SgrA I restrictions sites at nucleotide (nt) positions 3,219 and 3,614, 
respectively: both located within the C-terminal region of nsp2.  cDNAs coding for oligo- and 
polypeptide tags, including FLAG, enhanced green fluorescent protein (EGFP) and firefly 
luciferase were inserted into the newly created restriction sites. The results showed that only the 
EGFP-containing genomes were properly expressed and produced virus. EGFP fluorescence, but 
not EGFP immunoreactivity, was lost during passage of recombinant EGFP viruses in culture. 
Sequencing of a fluorescence-negative EGFP virus showed that the EGFP remained intact, 
except for the appearance of mutations that may affect chromophore formation.  The results 
show that nsp2 can be a site for the expression of foreign proteins. 
     Removal of the region between Mlu I and SgrA I sites resulted in a virus that contained a 131 
amino acid deletion. The deleted region was replaced with EGFP or an eight amino acid 
influenza hemagglutanin (HA) tag.  Recombinant viruses were used to infect pigs. Gross and 
micro-histopathology showed reduced pathogenesis when compared to the parent wild-type 
virus. The 131 amino acid peptide, when expressed as a recombinant protein and coated onto 
enzyme linked immunosorbent assay (ELISA) plates, was recognized by sera from pigs infected 
with wild-type virus, but not the deletion mutants. The results from this study show that nsp2 is a 
potential target for the development of marker vaccines that can differentiate infected from 
vaccinated animals (DIVA) and for virus attenuation.  
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INTRODUCTION 
     Porcine reproductive and respiratory syndrome (PRRS) was first observed in 1987 in the 
United States (20, 23) where it became widespread throughout North America. Initially, the 
disease was named mystery swine disease because of the elusive nature of its causal agent. Late 
in 1990, the first European outbreak of disease was reported in Germany, from where it spread 
rapidly throughout Europe (31). In mid-January 1991 the disease was reported in the Netherlands 
in breeding herds, and by the end of March it had spread over all provinces with intensive pig 
farming. In 1994, PRRS was officially recognized in 16 countries on three different continents; 
America, Asia and Europe (31). 
The etiologic agent responsible for the syndrome was first isolated on alveolar macrophage 
cultures by Wensvoort et al in Europe in 1991 (52) and was designated Lelystad virus (LV). 
Soon after that, the virus (ATCC VR-2332) was isolated on an MA104 derived cell line, CL 
2621, by Collins et al. (10) in the United States in 1992 and identified as the swine infertility and 
respiratory syndrome (SIRS) virus. 
      Initially several names were used to refer to the disease: mystery swine disease (23); swine 
infertility and respiratory syndrome (SIRS; 20) ; porcine epidemic abortion and respiratory 
syndrome (PEARS; 50); and blue-eared pig disease (53). However, porcine reproductive and 
respiratory syndrome (PRRS) is the name now commonly used and the one recognized by the 
International Office of Epizootics (O.I.E), leading to the causative agent being called porcine 
reproductive and respiratory syndrome virus (PRRSV). 
 
THE VIRUS 
     PRRSV is a small enveloped RNA virus that is classified as a member of the family 
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Arteriviridae (33), within the newly created order Nidovirales (8). The family Arteriviridae also 
includes equine arteritis virus (EAV), mouse lactate dehydrogenase 
elevating virus (LDV), and simian hemorrhagic fever virus (SHFV; 32, 43). PRRSV isolates are 
more closely related to LDV than to EAV (30, 32). Variations in antigenicity 
have been evidenced with polyclonal sera or monoclonal antibodies between the North American 
and European isolates (18, 28, 29) and among American isolates (27). Furthermore, the North 
American and European isolates have been shown to represent two distinct genotypes, now 
classified as PRRSV Type 1 for viruses of European lineage and PRRSV Type 2 for the North 
American lineage.  Type 1 and Type 2 genotypes share only about 67% identity at the nucleotide 
level  (29, 30). 
 
CLINICAL ASPECTS 
     PRRS initially emerged worldwide as a devastating clinical disease, characterized by a 
massive reproductive disorder affecting pregnant sows, perinatal losses and respiratory distress 
of piglets. PRRS is also seen by reduced growth performance during the grow-finish stage of 
production. Over time it became clear that the major characteristic of the disease was a high 
variability of clinical signs, including a smoldering subclinical course of infection. In retrospect, 
based on the presence of PRRSV antibodies in Canada and East Germany, PRRSV had already 
been circulating in herds before the report of outbreaks in North America and Europe (7, 40). 
      In its epidemic phase, PRRS is characterized in sow herds by massive reproductive disorders 
that last 1-3 months (11, 52). The onset of the infection in sows often starts with inappetence and 
anorexia, which, if the infection spreads on a large scale in a herd, is marked as a “rolling 
inappetence”. Occasionally, incidental cases of respiratory distress, fever or death have been 
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reported in sows. The reproductive disorders include abortion, premature birth, late term birth, 
increased incidence of fresh or autolytic stillborns, fetal death with or without mummification, 
and weak-born piglets that die shortly after birth. A less common finding, more often described 
in Europe, is a transient discoloration (cyanosis) of the ears, abdomen and vulva (53).   
      The disease in young pigs is characterized by respiratory disorders, increased mortality as a 
result of secondary infections and retarded growth (11, 52). The severity of clinical is largely 
age-dependent, i.e. more severe in nursery pigs compared to  finishing pigs. 
    Currently, PRRSV is endemic in most pig-producing countries throughout the world. Field 
studies have revealed that PRRSV can persist in herds for years (47, 50). Although limited 
clinical field studies of endemically infected herds are available, it is generally acknowledged 
that most infections are subclinical and productivity is usually maintained within acceptable 
parameters. In some infected herds, sporadic respiratory disease in young piglets or periodic 
reproductive disease in naïve sows have been reported (14). In the USA and the United 
Kingdom, the  recurrent respiratory disease problems in nursery and grower pigs are referred to 
as porcine respiratory disease complex (PRDC) and post-weaning respiratory syndrome ( 17, 47, 
55). In these herds, a higher than usual prevalence of secondary pathogens often occurs 
concurrently with PRRSV infections (42).  
 
IN VITRO GROWTH CHARACTERISTICS OF PRRSV 
         In the pig, PRRSV primarily targets alveolar lung macrophages. It was also recently shown 
to replicate in testicular germ cells such as spermatids and spermatocytes in infected boars (49). 
PRRSV can grow in vitro in primary cultures of alveolar lung macrophages and in African green 
monkey kidney cells or derivatives thereof (CL2621 or MARC-145; 3, 24). PRRSV can replicate 
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in several cell lines that cannot be infected by virus particles (35). This finding indicates that cell 
tropism is determined by the presence or absence of an as yet unidentified receptor on the cell 
surface. Recently monoclonal antibodies were produced that specifically bind to macrophages 
and prevent these cells from becoming infected by PRRSV (19). These MAbs recognize a 210-
kDa membrane protein, that might function as a putative receptor for PRRSV. Kim et al (2006) 
showed that simian vimentin could play an important role in transforming nonsusceptible cell 
lines into PRRSV permissive ones. A sialoadhesin and heparin receptor as well as CD163 are 
known to be a putative receptor of PRRSV. 
     PRRSV enters the host via the standard endocytotic route. Electron microscopy shows 
PRRSV particles in small vesicles, which appear to be clathrin-coated pits (26). Between 3-6 hr 
after infection, double membrane vesicles are formed (44). These are general features of 
arterivirus replication. For EAV, the double membrane vesicles are derived from the 
endoplasmic reticulum (ER) and contain the replication complex (41). PRRSV is assembled 
when preformed nucleocapsids bud into the lumen of the smooth endoplasmic reticulum or Golgi 
region or both. After budding, virions accumulate in vesicles, which move to the plasma 
membrane where they fuse to release the virus. In one-step growth experiments, the maximum 
release of PRRSV particles is between 10-20 h and the maximum titers in cell culture are 106.5- 
107.5 TCID50/ml. The cytopathic effect of PRRSV in macrophages and cell lines is characterized 
by rounding of the cells and detachment from the culture plate surface. 
 
GENOME ORGANIZATION 
     Genome sequencing of several PRRSV strains (12, 13) shows that PRRSV has a similar 
organization as other arteriviruses (45). The PRRSV genome is approximately 15 kb in length 
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and contains nine ORFs (Fig. 1.2). ORFs 1a and 1b comprise about 75% of the genome and 
encode the nonstructural proteins (nsp’s). The ORF1a and ORF1ab encoded polyproteins are 
processed into smaller protein products by virus-encoded proteases. For PRRSV, the first two N-
terminal cleavage products, nsp1α and nsp1β, have been shown to be papain-like cysteine 
protease (16). Based on studies of equine arteritis virus, cysteine protease (nsp2) and a serine 
protease (nsp4) are assumed to cleave the ORF1ab product into 12 nonstructural proteins (Fig. 
1.4). Still little is known about the function of the individual PRRSV nsps. Predictions relating to 
the functions of the ORF1b-encoded replicase subunits nsp9 and nsp10 are derived from 
comparative sequence analysis. A putative RNA-dependent RNA polymerase motif is present in 
nsp9, and a nucleoside triphosphate-binding/RNA helicase motif and metal binding domain are 
in nsp10 (2, 56). 
      The seven smaller ORFs,  2 through 7, are located at the 3’ end of the genome and encode 
structural proteins (13, 34). The nucleocapsid protein, N (ORF7) and the integral membrane 
protein M (ORF 6) are not glycosylated. In constrast, GP2a (ORF 2a), GP3 (ORF 3), GP4 (ORF 
4), and GP5 (ORF5) proteins are all N-glycosylated. Recently, a novel non-glycosylated 
structural protein, expressed from an ORF embedded in ORF2 and called ORF 2b codes for a 
small non-glycosylated protein known as 2b in PRRSV and E in EAV (46, 54).  
     The proteins derived from ORFs 2 to 7 are translated from a 3’ nested set of subgenomic 
mRNAs (Fig.1.2 and 1.3). The subgenomic mRNAs are composed of a leader sequence, derived 
from the 5’ end of the viral genome and fused to the subgenomic mRNA bodies by a 
discontinuous transcription mechanism (45, Fig. 1.3). The site of fusion, also called the leader-
body junction site, is a conserved sequence of six nucleotides : UUAACC. 
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GENOME TRANSLATION AND REPLICATION 
     By definition, the genome of a positive-stranded RNA virus fulfills a dual role in both storage 
and expression of genetic information. Thus, the reproduction of the arterivirus genomic RNA is 
a combined process of genome replication and mRNA transcription . For simplicity, I will use 
the term ‘replication’ for the process of genome (mRNA1) synthesis, whereas the term 
‘transcription’ will be used to refer to generation of the subgenomic mRNAs. 
     The PRRSV replication cycle starts with the expression of the replicase gene from the 
incoming genome. Replicase ORF1a and ORF1b, which is in the -1 reading frame relative to 
ORF1a, are both expressed from the genomic mRNA. ORF1b translation requires a ribosomal 
frameshift just before ORF1a translation is terminated (15). The ORF1a/ORF1b overlap region 
contains two signals which are assumed to promote this event (4) : a so-called ‘slippery’ 
sequence, which is the actual frameshift site, and a downstream RNA pseudoknot structure. In 
EAV, the putative shift site 5’ GUUAAAC 3’ is followed immediately by the ORF1a 
termination codon. In PRRSV and LDV, one additional codon is present between these two 
elements. The predicted stems 1 and 2 of the RNA pseudoknot typically consist of 11-12 and 6-7 
base pairs, respectively (15, 22, 33). The functionality of the arterivirus frameshift signal has 
only been demonstrated for EAV ; using a reporter gene construct, a frameshift efficiency of 15-
20% was observed (15).  
     In constrast to coronarviruses, little was known about the arterivirus RNA sequences required 
for genome replication.   Molenkamp et al (2000a, 2000b) described defective interfering (DI) 
particle of EAV, which showed the minimum genomic RNA sequence for viral replication and 
packaging. In the 3’ UTR, which displays 33-47% sequence identity among the arteriviruses, a 
short conserved sequence motif just upstream of the 3’ poly(A)-tail was desribed (22). At the 5’ 
 7
end, it is noteworthy that in three of the four arteriviruses the ORF1a initiation codon is located 
immediately downstream of the 3’ end of the common leader sequence (only in EAV are 12 
additional nucleotides present). As a result, the entire genome 5’ UTR is present in all 
subgenomic mRNAs of LDV, PRRSV and SHFV. Four host proteins from MA-104 cells were 
reported to bind to in vitro-generated transcripts representing the 3’ end of the SHFV genomic 
negative strand (21). This region, which is the complement of the genomic leader sequence, is 
assumed to be important for the initiation of plus-strand RNA synthesis. The same four proteins, 
which remain to be identified, interacted with transcripts representing the corresponding region 
of the LDV and EAV minus strands, suggesting the involvement of a common set of host factors 
in arterivirus plus-strand RNA synthesis. The RNA sequences required for encapsidation of the 
arterivirus genome remain to be determined. 
 
SEQUENCE VARIATION BETWEEN EUROPEAN AND NORTH AMERICAN PRRSV 
STRAINS 
     Extensive sequence analysis of field isolates of PRRSV has unexpectedly revealed high 
sequence variation between North American and European PRRSV isolates (1, 38, 48). The GP5 
protein is the most variable structural protein, with only 51-55% amino acid identity between 
North American and European isolates, whereas the M protein is the most conserved structural 
protein, with 78-81% amino acid identity.Sequence comparison between the ORF1 genes of 
Lelystad (LV) and two US strains (1) reveal major differences in this part of the genome. The 
greatest variation is observed in nsp2. The nsp2 protein of US strains is aprroximately 102 amino 
acids longer than that of LV and only share 32% identity at the amino acid level. Furthermore, 
differences in the leader-body junction sites that are used by European and US viruses are also 
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present. Although the leader-body junction sequence (UUAACC) is conserved in both European 
and North American isolates, the distance between the junction sequence and the downstream 
ORF is highly variable. Furthermore, additional junction sites that are less frequently used were 
identified for the North American strains VR2332 and ISU96 but not for LV (38). 
 
 
PREVENTION AND CONTROL 
     Despite the fact that PRRSV infection is widespread throughout the world, noninfected herds 
still exist. While all routes of virus introduction into a naïve herd are not completely understand 
at this time, the primary source is the infected pig. Therefore, it is critical to routinely isolate and 
test breeding stock before introducing them to a PRRS-negative herd. Replacement stock to be 
added to naïve herds should be obtained from known negative sources that carry out a regular 
schedule of herd monitoring. In addition, there should be clear and open communication between 
veterinarians responsible for the health of the source and recipient herds, respectively, prior to 
purchase of replacement stock. 
     Following the identification of PRRSV and the development of diagnostic tests, practitioners 
throughout the world have attempted to control the effects of PRRS. The initial attempts were 
based on the use of strategies known to be effective for controlling other diseases of swine (e.g., 
segregated early weaning). Recently, a model for the control of PRRS which focuses on the 
elimination of subpopulations was developed. The components of the model are as follows. 
(1) Understanding of the pattern of viral spread throughout the system through the application of 
population-based diagnostic strategies. (2) Proper development of replacement stock prior to 
introduction into PRRS-infected herds. (3) Prevention of the transmission of the virus from sow 
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to piglet through breeding-herd stabilization. (4) Control of the spread of virus in the nursery or 
finisher populations through weaned-pig management. The purpose of such a model is to provide 
a generally applicable systems approach for the control of PRRS-related disease problems. The  
individual components of the model described in greater detail as follows. 
 
PRRSV VACCINES 
     Several studies have established that vaccination against PRRS can result protective immunity 
(57, 58). Such studies have led to the extensive use, especially in the United States, of 
commercial vaccines as an aid in reducing the clinical consequences of infection with virulent 
PRRSV. Although both attenuated and inactivated vaccines have been described, the former are 
generally believed to be more efficacious. As a result, virus inactivation has been used mostly as 
a method of preparing autogenous vaccines. 
     Currently, two attenuated vaccines are commercially available for use as an aid in the 
prevention and control of PRRS. RespPRRS/Repro® has been marketed in North America since 
1994 for administration to pigs between 3 and 18 weeks of age for the prevention of the 
respiratory component of PRRS, and since 1996 for administration to nonpregnant gilts and sows 
for the prevention of the reproductive component of PRRS (The same vaccine is marketed in 
Europe under the name Ingelvac® PRRS MLV). Prime Pac® PRRS has been marketed in the 
United States since 1996 for administration to nonpregnant gilts and sows for the prevention of 
the reproductive component of PRRS. 
     Much of what is now known about vaccination against PRRS is based on controlled 
laboratory studies with RespPRRS/ Repro® and with three experimental vaccines developed at 
the National animal Disease Center (NADC) (58). All of these vaccines, as well as Prime Pac® 
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PRRS, were derived (i.e., attenuated) by repeated passage of virulent, North American field 
strains of PRRS virus in cell culture. They differ genetically from one another to some extent, 
but they are more closely related to each other than to Lelystad (LV) virus. 
     Information from fields use of PRRS vaccine is limited mostly to RespPRRS/ Repro®, which 
has been used extensively since it was first licensed and marketed in 1994 under the name 
RespPRRS/ Repro®. Although RespPRRS® was not approved for use in gilts and sows for the 
prevention of the reproductive component of PRRS until 1996 (When the name was changed to 
RespPRRS/Repro®). 
     The following discussion relative to the safety, efficacious, and limitations of PRRS vaccines 
is based almost entirely on information derived from laboratory studies with RespPRRS/Repro® 
and NADC vaccines and from field use of RespPRRS/Repro®. The relative merits of the more 
recently introduced Prime Pac® PRRS remain to be determined. 
     It is generally believed that, when used judiciously, attenuated vaccines can be of value in 
preventing and controlling PRRS. However, to achieve greatest success a number of factors need 
to be considered when designing a vaccination program. (1) Vaccines virus can persist for weeks 
and perhaps months (59), and its persistence may be similar to that of virulent virus (58,60). (2) 
Vaccines virus can be transmitted from vaccinated pigs to naïve pigs (61, 62). (3) Vaccines virus 
can persist in boars and be disseminated through semen (63). (5) Vaccine-induced protective 
immunity is slow to develop (59). (6) The time required to develop protective immunity is likely 
to be strain related; that is, immunity may develop more quickly and more forcefully and last 
longer against the homologous and antigenically similar strains than against more distantly 
related strains of PRRSV. (7) Some vaccinated pigs, gilts, and sows may fail to seroconvert for 
PRRSV following vaccination (Mengeling and Lager, unpublished data). (8) Successful 
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vaccination of adult females (as judged by seroconversion) may not ensure the complete absence 
of transplacental infection and vertical transmission of virulent virus (59). In addition, evidence 
has been presented for the transmission of vaccine virus from vaccinated sows to nonvaccinated 
sows, and from vaccinated herds to nonvaccinated herds, with the subsequent development of 
vaccine-virus-induced reproductive failure (61). 
     Although vaccines, especially attenuated vaccines, have played a role in the prevention and 
control of PRRS and are likely to continue to do so in the foreseeable future, there is still much 
to be learned about their efficacy and safety and about the minimal interval between vaccination 
and exposure to virulent virus necessary for protective immunity. And because of the strain 
differences there may be a need for multistrain vaccines to provide the earliest protection against 
the widest range of heterologous strains. Also, inactivated vaccines (63), because of their added 
level of safety, need to be further evaluated for their potential for the control of PRRS, either 
when used alone or as an adjunct to attenuated vaccines. 
 
INFECTIOUS cDNA CLONES 
     The development of infectious cDNA clones is a major breakthough in PRRSV research and 
allows the construction of genetically-engineered mutant PRRS virus in vitro (35, 5, 6, 39, 51, 
9). When the transcripts of a cDNA clone are transfected to BHK-21 or MARC-145 cells, 
progeny virus is produced which can be further propagated in porcine alveolar macrophages or 
MARC-145 cells. The genomic transcripts are first transfected into BHK-21 cells because these 
cells are more efficiently transfected than CL2621 cells or other PRRSV propagating cell lines. 
Although PRRSV cannot enter BHK-21 cells, once the genomic RNA is introduced into these 
cells, the virus is produced.  In the published literature, there are several examples of specific 
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modifications to the PRRSV genome, including mutations, deletions, substitutions, and foreign 
gene expression (5, 6, 9).  However, only a few mutations are tolerated by the virus, indicating 
that the major part of the genomic RNA contains essential sequences for virus replication. 
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Fig. 1.1. Schematic presentation of the virus particle of PRRSV and the location of the structural 
proteins GP2-GP5, M and N. 
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Fig. 1.2. Genome organization of PRRSV. The replicase gene, consisting of the open reading 
frame (ORFs) 1a and 1b, encodes a polyprotein that is cleaved, forming smaller protein products 
designated as nonstructural proteins (nsp 1-12). ORF1 is followed by ORFs 2 to 5 encoding 
glycoproteins GP2 to GP5 ; ORF6 encodes the membrane protein M ; and ORF7 encodes the 
nucleocapsid protein N. An internal ORF present within ORF2 encodes 2b. 3’ nested set of 
subgenomic mRNAs synthesized during PRRSV replication. The 5’ leader (thin blue box), 
derived from the genomic RNA and fused to the subgenomic RNAs, is shown. Leader TRS 
(Transcription regulating sequence; thick red box) ; Body TRS (thick blue box) ; RFS 
(Ribosomal frameshifting ; purple box). 
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Fig. 1.3. Model for nidovirus subgenomic RNA synthesis by discontinuous extension of minus 
strands. Whereas, genome replication relies on continuous minus strand synthesis (antigenome), 
subgenomic minus strands are produced by atteunuation of nascent strand synthesis at a body 
TRS (red bar), followed by translocation of the nascent strand to the leader TRS in the genomic 
template. Following base-pairing between the body TRS complement at the 3’ end of the minus 
and the leader TRS, RNA synthesis would resume to complete the subgenomic minus strand that 
would then serve as template for the transcription of subgenomic mRNAs. 
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Fig. 1.4. Nidovirus replicase comparison. The replicase gene organization of the arteriviruses 
EAV and porcine reproductive and respiratory virus (PRRSV) and coronavirus SARS-CoV are 
depicted in the form of polyprotein pp1ab. The border between ORF1a- and ORF1b-encoded 
residues is indicated as RFS (ribosomal frameshift). Gray and black arrows represent the sites 
that are cleaved by accessory papain-like protease (AP) and the main (3C-like) protease (MP), 
respectively. The proteolytic cleavage products are numbered, and within the cleavage products, 
the location of the domain that have been identified as structurally or functionally related are 
indicated in black boxes. These include the four nidovirus-wide conserved domains encoded by 
ORF1b (RdRp, zinc-binding domain [Z], helicase [HEL], and NendoU [N]), putative 
transmembrane domain (TM), coronavirus-specific conserved domains (Ac, X, Y, Exo, and 
MT), and one SARS-CoV specific insertion (SUD). Note that the arterivirus and coronavirus 
polyprotein are drawn to different scales. 
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CHAPTER 2 
The expression and stability of foreign tags inserted into nsp2 of porcine reproductive and 
respiratory syndrome virus (PRRSV) 
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ABSTRACT 
     The nonstructural protein 2 (nsp2) of porcine reproductive and respiratory syndrome virus 
(PRRSV) is the single largest protein produced during virus replication. The cDNA of the 
pCMV-129 infectious PRRSV clone was modified by creating unique Mlu I and SgrA I 
restrictions sites at nucleotide (nt) positions 3,219 and 3,614, respectively: both located within 
the C-terminal region of nsp2.  cDNAs coding for oligo- and polypeptide tags, including FLAG, 
enhanced green fluorescent protein (EGFP) and firefly luciferase were inserted into the newly 
created restriction sites. The results showed that only the EGFP-containing genomes were 
properly expressed and produced virus. EGFP fluorescence, but not EGFP immunoreactivity, 
was lost during passage of recombinant EGFP viruses in culture. Sequencing of a fluorescence-
negative EGFP virus showed that the EGFP remained intact, except for the appearance of 
mutations that may affect chromophore formation.  The results from this study show that nsp2 
can be a site for the expression of foreign proteins and creates the possibility of constructing 
marker viruses for the study of virus replication. 
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INTRODUCTION 
     Porcine reproductive and respiratory syndrome virus (PRRSV), a member of the family 
Arteriviridae, is an economically important disease of swine.  Other members of the arterivirus 
family include lactate dehydrogenase-elevating virus (LDV) of mice, equine arteritis virus 
(EAV), and simian hemorrhagic fever virus (SHFV : see review 22). Arteriviridae along with the 
Coronaviridae, and the recently established Roniviridae belong to a relatively new order, 
Nidovirales (8).  Arterivirus reverse genetic systems have greatly improved the understanding of 
arterivirus RNA replication, subgenomic mRNA synthesis and the role of cis-acting elements 
required for RNA packaging (1, 2, 3, 26, 14, 16, 25).  The inclusion of foreign genes also 
provides the opportunity to develop marker viruses, which can be used in studies of virus 
replication, gene function and pathogenesis. One approach for creating a marker virus is the 
insertion of cDNA into one of the structural genes.  For example, the chloramphenicol 
acetyltransferase (CAT) gene was inserted into ORF2 of EAV, but without the production of 
infectious virus (26). A cDNA fragment encoding the influenza virus hemagglutinin (HA) was 
ligated into the 5’ or 3’ end of the nucleocapsid (N) gene, ORF7, of PRRSV (9).  However, the 
synthesis of the resulting HA-N fusion protein resulted in nonviable progeny virus. Another 
approach is to create a cassette, containing a marker, with an upstream transcription regulating 
sequence (TRS). The result is the synthesis of an additional subgenomic mRNA encoding the 
gene of interest. This approach was used to express EGFP in EAV and PRRSV (5, 1, 2, 27, 12). 
In both cases, the recombinant arterivirus expressed EGFP fluorescence and replicated to the 
same levels as the parental virus. 
     The approach incorporated in this study was the insertion of a marker into the 12 kb region 
occupied by the non-structural proteins (nsp’s). The nsp’s of PRRSV are produced as the result 
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of the proteolytic processing of the pp1a and pp1b polyproteins, which are translated from 
ORF1a and ORF1ab, respectively.  The complete processing of pp1a and pp1ab is predicted to 
yield 12 nsp polypeptides (15, 29, 30). The relatively large nsp2 region of North American 
PRRSV isolates occupies amino acids 383 to 1263 within pp1a (15).  Based on studies of EAV, 
nsp2 is predicted to contain a cysteine protease domain in the N-terminal end, which is 
responsible for proteolytic cleavage of the nsp2/3 junction (15, 22, 28). The C-terminal end 
interacts with nsp3 and together these form a scaffolding complex that supports the formation of 
double membrane vesicles and replication complexes (21, 22, 23, 28). Genetic sequence 
comparisons of PRRSV isolates identified a hypervariable region in nsp2 that naturally 
incorporates both nucleotide insertions and deletions (20, 7). Based on these properties, we 
reasoned that nsp2 could support the insertion of foreign proteins. 
 
MATERIALS AND METHODS 
Cells. 
     MARC-145 cells and BHK-21 cells were maintained in Eagle’s MEM with 7% FBS and 
supplemented 0.008% Fungizone and 0.01% penicillin-streptomycin.  The MARC-145 cell line, 
a derivative of MA-104 cells (11), was used in those experiments involving PRRSV infection. 
Porcine alveolar macrophage (PAM) cells were obtained from the lungs of four to six week-old 
pigs by lung lavage with PBS. Cells were plated in RPMI with 10% FBS with antibiotics. After 
two days, cells were infected with virus. Virus yield was measured by end-point titration of 
virus-containing culture media on MARC-145 cells. Serial 10-fold dilutions of virus were placed 
on 96-well tissue culture plates containing MARC-145 cells.  After 3 days, plates were fixed in 
80% acetone then stained with SDOW-17.  Results were reported as TCID50/ml (19). 
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Introduction of Mlu I and SgrA I restrictions site into nsp2 of pCMV-S-129. 
     Insertion of unique restriction sites into nsp2 region of pCMV-S-P129 infectious clone was 
performed using the QuikChange® II XL Site-Directed Mutagenesis kit (Stratagene). Sequences 
for forward and reverse primers used to insert the Mlu I and SgrA I sites are shown in Table 1. 
QuikChange II XL reactions were as recommended by the manufacturer and contained 150 
picomoles of each primer and 10 ng of plasmid DNA as template.  Reaction conditions included 
an initial denaturation step at 95˚C for 60 seconds followed by 18 cycles of 95˚C (50 sec), 60˚C 
annealing (50 sec), and 68˚C extension (20 sec). The reaction was concluded with a 7-minute 
incubation at 68˚C.  The insertion of the unique restrictions sites was performed in two steps and 
shown in Fig. 1. First, the Mlu I site was created at position 3,219 by performing site-directed 
mutagenesis on the full-length infectious clone. The changing of only two nucleotides allowed 
the introduction of a Mlu I site without altering the encoded amino acid sequence. The plasmid 
was named pCMV-S-129-Mlu. To create the SgrA I site, the infectious clone was cut with Mlu I 
and Pme I and subcloned into a shuttle, pCR-XL-3201-7700. A naturally occurring Pme I site is 
located at nt position 7,701, within nsp8. Site-directed mutagenesis was performed on the shuttle 
vector to create the SgrA I site at nt position 3,614. The shuttle vector was cut with Mlu I and 
Pme I and ligated into the Mlu I and Pme I sites in the full-length cDNA clone to create the 
plasmid pCMV-S-129-Mlu-SgrAI. 
Transfection of MARC-145 and BHK-21 cells on twelve well plates was performed with 2 ug of 
plasmid DNA using LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s 
recommendations.  
 
Antibody detection of FLAG, EGFP and PRRSV nucleocapsid (N) protein  
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      Cells grown on plastic plates were fixed in 80% acetone for 10 min and then air-dried. All 
antibodies were diluted in PBS with  5% FBS (PBS-FBS).  Except where indicated, all 
incubations were performed at 37o C for one hr followed by extensive washing with PBS. For 
detection of the FLAG epitope tag, cells were stained for two hr with anti-FLAG antibody 
(Molecular Probes) diluted 1:200. Cells were incubated with a 1:500 dilution of AlexaFluor 584-
labeled anti-rabbit antibody (Molecular Probes) and visualized under a fluorescence microscope. 
The immunological detection of the EGFP protein was performed by staining cells for one hr 
with a 1:200 dilution of goat anti-GFP antibody (Rockland), followed by staining with 
peroxidase-labeled rabbit anti-goat antibody (Sigma-Aldrich) diluted 1:1,000 in PBS-FBS and 
incubated for one hr. Peroxidase activity was detected using a DAB substrate system (Amresco). 
PRRSV nucleocapsid (N) protein antigen was detected using the anti-N protein mAb antibody, 
SDOW-17 (a kind gift of Eric Nelson, South Dakota State University).  Cells were incubated 
with SDOW-17 for one hour followed by staining with AlexaFluor 594-labled goat anti-mouse 
IgG antibody.  AlexaFluor 594 was detected with an A540 cutoff fluorescence filter.  
 
Confocal microscopy 
     Glass coverslips of  pCMV-Mlu-EGFP-SgrA infected MARC-145 cells were washed with 
PBS, fixed for 10 minutes with 2% paraformaldehyde in PBS. Cells were counterstained with the 
nuclear stain, TO-PRO-3. Coverslips were mounted and viewed under a Zeiss LSM 510 confocal 
microscope. 
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 RT-PCR for the detection of the EGFP insert  
     The presence of the EGFP insert in nsp2 was detected by reverse transcription-polymerase 
chain reaction (RT-PCR) amplification of total RNA from media of virus-infected cells. Total 
RNA was isolated from cells using a TRIzol, (Invitrogen). The primers chosen for RT-PCR 
amplification flanked the EGFP insert. The sequence of the 2941F and 3421R forward and 
reverse primers were 5’-AGCCAATTTTTGTGTCTGCACTGCAACACAAATTT-3’ and 5’–
CCCAAACCTGCCATCTAAGGTGCGAAACGCCTGGT-3’, respectively. 
Viral RNA was reverse transcribed using SuperScript III (Invitrogen) and the 3421R primer. 
Amplification was performed using TaKaRa Ex TaqTM according to the manufacture’s 
recommendations. Reaction conditions included an initial denaturation step of 95˚C for 60 
seconds followed by 30 cycles of 94˚C (35 sec), 58˚C annealing (35 sec), and 72˚C extension (1 
min). The reaction was concluded with a 10-minute incubation at 72˚C. PCR products were 
separated on an agarose gel and stained with ethidium bromide. PCR products were cloned into 
pCR2.1 TOPO vector (Invitrogen) according manufacturer’s instruction, expressed in E. coli, 
and sequenced in both directions using M13 forward and reverse primers, which were located in 
the pCR2.1 vector.  
 
RESULTS 
Expression properties of oligo- and polypeptide tags in nsp2 of pCMV-S-P129. 
     Site-directed mutagenesis was used to introduce unique Mlu I and SgrA I restriction enzyme 
sites at nucleotide positions 3,219 and 3,614 of  pCMV-S-129, a DNA-launched PRRSV 
infectious clone (12).  The creation of the sites required changing only two nucleotides for the 
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introduction of the Mlu I site and only a single nucleotide change for the creation of the SgrA I 
site (see Table 1). Both sites were created without altering the encoded amino acid sequence.  
The restriction sites are located within the C-terminal region of nsp2 and are distant from the N-
terminal histidine and cysteine residues involved in nsp2 cysteine protease function, and are also 
distant from the conserved C-terminal end.    
     Nsp2 possesses considerable nucleotide and peptide sequence hypervariability, including the 
capacity to support significant insertions and deletions (20, 6, 18, 7).  To better understand 
peptide sequence hypervariability as it related to the location of the Mlu I and SgrA I sites, the 
nsp2 peptide sequences from 14 PRRSV isolates, obtained from GenBank and our lab, were 
aligned using CLUSTALX (24). The resulting histogram, presented in Fig. 2.2B, shows the 
number of substitutions for each 10 amino acids versus the amino acid position in nsp2.  The 
results confirmed that the peptide sequence in C-terminal region of nsp2 is highly variable.  
However, hypervariability was not uniform across the region but contained two hypervariable 
regions, we call HV-1 and HV-2,  which flank a more conserved region. The site chosen for the 
insertion of the Mlu I site lies within this island of relatively conserved amino acids.  In contrast, 
the SgrA I site is located within a highly variable domain, we call HV-2.  It is interesting to note 
that the SgrA I site is in the same vicinity as a naturally occurring insertion of 250 amino acids in 
the PrimePak PRRSV isolate (20).   
      The investigation into the expression of foreign cDNA tags in nsp2 incorporated the cloning 
of three different-sized cDNAs into the Mlu I site of pCMV-S-P129-Mlu (Fig. 2.2A). The first 
insertion was a 24 bp cDNA encoding the 8 amino acid FLAG oligopeptide, DYKDDDDK 
(pCMV-S-P129-Mlu-FLAG).  The second was the insertion of a 798 bp cDNA, which coded for 
the enhanced green fluorescent protein (EGFP; pCMV-S-P129-Mlu-EGFP). And finally, we 
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chose a 1650 bp cDNA coding for firefly luciferase (pCMV-S-P129-Mlu-LUC). PCR 
amplification, incorporating primers with Mlu I restriction sites on the 5’ and 3’ ends of each 
cDNA were used to clone each tag into the Mlu I site of the infectious clone. The correct 
orientation and sequence of each inserted fragment was confirmed by DNA sequencing 
incorporating primers that flanked the Mlu I site of the infectious clone. Plasmids were 
transfected into baby hamster kidney (BHK-21) and MARC-145 cells.  The use of BHK-21 cells 
was based on earlier observations showing increased transfection efficiency of BHK cells (14, 
16).  When checked at 24 and 72 hr after transfection with pCMV-S-P129-Mlu-FLAG, both cell 
lines were negative for anti-FLAG staining. However, media from cells at 72 hr after transfection 
contained viable virus, as demonstrated by the presence of positive staining with the anti-
nucleocapsid antibody at two days after infection of MARC-145 cells (data not shown).  
     The transfection of MARC-145 cells with pCMV-S-P129-Mlu-EGFP resulted in the 
appearance of single cells with green fluorescence, which first became visible at about 12 hr after 
transfection.  By three days, the individual cells were replaced with clusters of fluorescent cells 
indicating that virus had spread to adjacent cells.  An example of a fluorescent focus at four days 
after transfection of MARC-124 cells is shown in Fig. 3A.  The transfection of BHK-21 cells 
with the pCMV-S-P129-Mlu-EGFP  produced single fluorescent cells at 24 hr, which eventually 
disappeared without the formation of foci. This result is consistent with the non-permissiveness 
of BHK-21 cell for PRRSV infection.  The P129-MLU-EGFP virus obtained at four days after 
transfection of MARC-145 cells with pCMV-S-P129-Mlu-EGFP was used to infect PAMs. 
Within 24 hr,  EGFP expression was clearly visible (see photomicrograph in Fig. 2.3B), 
indicating that the P129-MLU-EGFP  virus was capable of infecting porcine macrophages. Two 
additional EGFP-expressing constructs were made. The first incorporated the insertion of EGFP 
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cDNA into the SgrA I site, to produce the virus P129-SGR-EGFP (see Fig. 2.2A).  The second 
plasmid, pCMV-S-P129-Mlu-EGFP-Sgr, was made by adding Mlu I and SgrA I sites to the 5’ 
and 3’ ends of EGFP, respectively, and then ligating the EGFP cDNA into the Mlu I and SgrA I 
sites of the infectious clone.  The resulting virus, P129-MLU-EGFP-SGR contained a 
replacement of the 395nt Mlu I- SgrA I fragment with the 798 nt EGFP (see Fig. 2.2A). The two 
new EGFP constructs possessed the same properties as the P129-MLU-EGFP virus, including 
the formation of fluorescent foci cells and infection of porcine alveolar macrophage (PAM) (data 
not shown).  
During arterivirus replication, nsp2 is predominately perinuclear where it associates with double 
membrane vesicles (DMVs), which contain the replication complexes (31, 32). MARC-145 cells 
infected with  P129-MLU-EGFP-SGRA were fixed at 24 hr after infection and counterstained 
with the nuclear stain TO-PRO-3. As shown in Fig. 2.4, EGFP was found in the cytoplasm with 
an accumulation of fluorescence around the nucleus. This result indicates that the localization of 
the nsp2-EGFP fusion protein is consistent with nsp2. 
     Luciferase activity was measured in MARC-145 cells after transfection with pCMV-S-P129-
Mlu-LUC. For the purpose of comparison, the plasmids, pISRE-Luc and pCMV-S-P129, were 
included as positive and negative controls, respectively. The level of luciferase activity at 24 hr 
after transfection of MARC-145 cells with pCMV-S-P129-Mlu-Luc was equivalent to the level 
obtained from cells transfected with the positive control (Fig. 2.3C); whereas, cells after 
transfection with the pCMV-S-P129 remained negative for luciferase activity. Even though the 
pCMV-S-P129-Mlu-Luc cells were positive for luciferase, PRRSV N protein antigen was not 
detected, and media obtained at 4 days after transfection was negative for the presence of virus. 
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These results indicate that luciferase activity was present, but without the production of 
infectious virus. 
 
Replication properties of recombinant viruses 
       Yields of the recombinant viruses obtained four days after the transfection of MARC-145 
cells were measured using MARC-145 and PAM cells. The results, presented in Fig. 2.5, showed 
that all recombinant viruses, except for P129-LUC, replicated in MARC-145 cells and PAMs. 
The yields of recombinant EGFP and FLAG viruses was similar to the P-129  parent virus. Virus 
yields for the P129-MLU-EGFP and P129-SGR-EGFP viruses were reduced by 1 to 2 logs, but 
recovered to P129 levels after a single passage on MARC-145 cells. These results demonstrate 
that the insertion of EGFP into the Mlu I or SgrA I sites does not affect the in vitro replication 
properties of the P129 virus.  The replacement of 132 amino acids in nsp2 with EGFP, in the 
virus P129-MLU-EGFP-SGR, also had no significant effect on virus replication.  
 
Stability of EGFP expression 
     To study the stability of EGFP expression by recombinant PRRS viruses, fluorescence was 
followed during serial passage of P129-MLU-EGFP and  P129-MLU-EGFP-SGR viruses on 
MARC-145 cells.  Viral passage was initiated by harvesting media at three days after 
transfection with plasmid and placing a 1:100 dilution of culture supernatant on a fresh 
monolayer of MARC-145 cells.  The second passage was performed in a similar manner using 
media from infected cells. After a total of five passages of the P129-MLU-EGFP virus on 
MARC-145 cells, EGFP fluorescence had disappeared (Fig.2. 6A). The presence of virus was 
confirmed by positive staining for the N protein (Fig.2. 6B).  Even though EGFP fluorescence 
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was absent, infected cells still expressed the EGFP polypeptide, which was evident by positive 
staining with a polyclonal anti-GFP antibody (Fig. 2.6C).  Since the DAB chromogenic substrate 
used to detect the peroxidase activity in anti-GFP stained cells destroyed EGFP fluorescence, 
anti-GFP staining was performed on a duplicate well of infected cells. In contrast to the P129-
MLU-EGFP,  the P129-MLU-EGFP-SGR virus produced fluorescent foci after five passages 
(see Fig. 2.6D and E).  However, there were several nucleocapsid-positive cells that lacked 
EGFP fluorescence suggesting that some viruses within the population had become fluorescence 
negative (see arrow in Fig. 2.6E).   As expected, the P129-MLU-EGFP-SGR foci reacted with 
the anti-GFP antibody (Fig. 2.6F).  The results indicate that EGFP fluorescence, but not EGFP 
immunoreactivity, is lost during serial passage of EGFP viruses.  However, the replacement of 
the 132 amino acid region between Mlu I and SrgA I, with EGFP was able to improve the 
stability of fluorescence expression (set up the duplication) 
     RT-PCR products containing the EGFP region were generated by amplifying the region 
flanking the Mlu I sites in P129-MLU-EGFP. The results, presented in Fig. 2.7A, showed that 
the predicted 1378 bp product, was obtained for each passage, indicating that the EGFP insert 
remained intact. To better understand the mechanism for loss of fluorescence, we sequenced the 
EGFP PCR product from the P5 virus. There were only two point mutations in EGFP: both 
resulted in a change in amino acid. The first was a change from arginine to cysteine at position 
96 and the second, a change from asparagine to tyrosine at position 106 (See Fig. 2.7B).  There 
were no mutations in the region of the cDNA product flanking the EGFP insert.  
 
DISCUSSION 
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      The insertion of foreign oligo- and polypeptide sequences into nsp2 of PRRSV provides the 
opportunity to develop marker viruses for use in studies of virus replication and nsp2 function. 
The choice of nsp2 as a site for foreign protein insertion was based on its large size and natural 
capacity to support the insertion of polypeptides.  The incorporation of fluorescent tags, such as 
EGFP, provides the mean to follow replication in live cells over time. Since the level of 
fluorescence in a culture well provides a semi-quantitative measurement of virus replication, 
EGFP-labeled viruses can be incorporated into high throughput screening methods for the 
identification of antiviral compounds.  
      This study identified some potential limitations in the types of tags suitable for insertion into 
the Mlu I and SgrA I restriction sites chosen in this study. One cDNA fragment, encoding the 
FLAG peptide tag, DYKDDDDK,  inserted into the Mlu I site was not detected in transfected 
cells but resulted in the release of viable virus into the media (Fig. 2.5).  To determine if the 
absence of antibody recognition was unique to the FLAG tag, we constructed a similar plasmid 
incorporating the HA sequence, YPYDVPDY.  Again, viable virus was generated, but with the 
same negative antibody staining result (data not shown).  The absence of detection of small 
oligopeptide tags could be related to the location of the tag within nsp2.  For optimal detection, 
small oligopeptide tags are typically placed on the N- or C-terminus of a protein, which allows 
for easy access for binding an anti-tag antibody.  In this study, the peptide tags were embedded 
within nsp2, with large polypeptides regions flanking the insertion site. The folded protein may 
bury the tag, making it inaccessible to antibody.  We also investigated the properties of a 
relatively large luciferase cDNA inserted into the Mlu I site.  Luciferase activity was readily 
detected after transfection of the pCMV-129-S-Mlu-Luc plasmid (Fig. 2.3C), but without the 
production of replication competent virus or the synthesis of nucleocapsid protein.  Nsp2 is 
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essential for the synthesis of genome, anti-genome and subgenomic mRNAs. Therefore, the 
absence of nucleocapsid antigen expression after transfection with the pCMV-S-P129-Luc 
plasmid suggests that the ORF7 subgenomic mRNA was not being properly synthesized.  The 
likely effect of the insertion of luciferase is the inhibition of nsp2 function.  Since PRRSV is a 
positive stranded RNA virus, the source of the nsp2-luciferase-containing transcript is from the 
full-length genomic RNA driven by the CMV promoter on the pCMV-S-129-Mlu-Luc plasmid. 
     BHK-21 and MARC-145 cells transfected with pCMV-S-P129-Mlu- EGFP produced both 
green fluorescent cells and viral progeny. PAM cells supported the replication of the MARC 145 
cell-derived EGFP viruses (Fig. 2.3B).  Cells infected with EGFP recombinant viruses expressed 
EGFP fluorescence to relatively high levels. The distribution of EGFP fluorescence was 
predominately cytoplasmic and perinuclear (Fig.2. 4), consistent with the localization properties 
of arterivirus nsp2 (32).  After five passages of the P129-MLU-EGFP virus, fluorescence had 
disappeared. However, viral foci stained positive with an anti-GFP polyclonal antibody, 
indicating that the EGFP was still immunologcally intact (see Fig. 2.6). Fluorescence was 
maintained longer during the serial passage of P129-MLU-EGFP-SGR, but fluorescence was 
eventually lost after further passaging on MARC-145 cells.   
     RT-PCR, incorporating primers that flanked the EGFP insert of P129-MLU-EGFP, showed 
that the size of the insert remained intact over eight passages (Fig. 2.7A).  DNA sequencing of 
EGFP and the flanking regions of a virus after five passages showed two mutations in EGFP, an 
Arg to Cys change at position 96 and a Asn to Tyr change at position 106.  The chromophore of 
EGFP is formed by Thr-65, Tyr-66 and Gly-67, which are embedded within a barrel strucuture 
formed by 11 anti-parallel beta sheets (4, 17).  After translation, the nascent EGFP polypeptide is 
non-fluorescent. Fluorescence becomes active after the formation of an imidazolidinone ring by 
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Tyr-66 and Gly-67 followed by the auto-oxidation of Tyr-66. Mutations in the chromophore, 
nearby amino acid residues, or amino acids residues involved in the formation of the beta-barrel 
can inactivate fluorescence (13). The tertiary structure of GFP, derived from X-ray 
crystallographic studies (17), shows that Arg-96 forms a hydrogen bond with the carbonyl group 
of the imidazolidinone ring. Arg-96 is likely to participate in the formation or stabilization of the 
Tyr-66/Gly-67 ring structure (17).  Therefore, a change from Arg-96  to Cys-106 may prevent 
fluorescence by blocking the formation of the imidazolidinone ring.  Additional support for 
mutations that affect chromophore formation comes from the nucleotide sequence analysis of 
three fluorescence-negative isolates from pigs infected with P129-MLU-EGFP-SGR. One isolate 
possessed a Tyr to Ser change at position 66, within the tri-peptide chromophore. The second 
isolate possessed a Tyr to His change at position 66 along with the Arg to Cys mutation at 
position 96.  The third possessed a deletion that covered the chromophore region.  
     Even though it appears that nsp2 can easily tolerate the insertion of EGFP, the accumulation 
of point mutations in amino residues that affect chromophore formation suggests that the 
chromophore may affect nsp2 function. EGFP is a commonly used tag in virology and cell 
biology. The possibility that chromophore formation can affect the function of the fusion partner 
is a unique observation. The mechanism for how chromophore formation might affect nsp2 
function remains to be determined.    
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 Table 2.1- Primers used for introducing Mlu I and SgrA I sites in nsp2 of pCMV-S-129* 
 
3219 Mlu I  
Forward 5’CTGTCAAGTGTTAGGATCACGCGTCCAAAATACTCAGCTC 
Reverse 5’ GAGCTGAGTATTTTGGACGCGTGATCCTAACACTTGACAG 
 
SgrA I (3597-3637)     
Forward 5’CTCGGGAAAATAGAAAACACCGGTGAGATGATCAACCAGGG 
Reverse 5’CCCTGGTTGATCATCTCACCGGTGTTTTCTATTTTCCCGAG 
*Restriction sites are underlined. Mutations needed to create the restriction sites are in 
bold.  
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FIG. 2.1. Insertion of unique Mlu I and SgrA I cloning sites into nsp2 of the pCMV-S-129 
infectious cDNA clone. The Mlu I site was introduced at genome position 3,219 of the pCMV-S-
P129.  The SgrA I site was inserted after subcloning the Mlu I-Pme I fragment to produce the 
shuttle vector pCR-XL-3201-7700 followed by the insertion of the SgrA I site. The Mlu I-Pme I 
fragment was then ligated into pCMV-S-129 cDNA.  
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Fig. 2.2  Recombinant viruses used in this study. (A) Location of olig-peptide and polypeptide 
tags in nsp2. Asterisks identify the location of histidine and cyteine residues which are conserved 
among the arteriviruses and form part of the protease active site.  (B) Location of Mlu I and Sgr 
A I sites within the conserved and hypervariable regions in nsp2. Nsp2 peptide sequences from 
14 PRRSV isolates were aligned using Clustal-X. The bar graph shows the number of amino acid 
substitutions along the nsp2 peptide sequence. Each bar represents 10 amino acids. Location 
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chosen for the insertion of the Mlu I and SgrA I sites are identified by arrows.  Two 
hypervariable domains are identified as HV-1 and HV-2. The nsp2 sequences were obtained 
from GenBank as well as our lab isolate, SD23983.  The viruses and GenBank accession 
numbers used to create the graph were VR-2332(AY150564), SP(AF184212), 
01NP1.2(DQ056373), BJ-4(AF331831), PL97-1(AY582141), CH-1a(AY032626), HB-
2(sh)/2002(AY262352), JA142(AY424271), NVSL(AY545985), P129(AF494042), 
HN1(AY457635), PA8(AF176348), RespPRRSV (AF066183). 
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Fig.2.3.  Properties of EGFP and luciferase recombinant viruses. (A) The formation of a single 
focus of EGFP fluorescing cells in a monolayer of MARC-145 cells. The photomicrograph was 
taken at four days after transfection with pCMV-S-P129-Mlu-EGFP. (B) EGFP fluorescence in 
PAM cells infected with virus derived from pCMV-S-P129-Mlu-EGFP-transfected MARC-145 
cells. Photomicrograph was taken at one day after infection with an m.o.i. of approximately 10 
TCID50/cell. (C) Luciferase activity in MARC-145 cells transfected with pCMV-S-P129-Mlu-
Luc. pISRE-Luc and pCMV-S-P129 were used as positive and negative controls, respectively. 
Measurements were made at 24 hr after transfection. Cell lysates were analyzed for luciferase 
activity using the Luciferase Assay System (Promega) and a Lumax luminometer (Molecular 
Technologies). Values are presented as the mean values of two independent experiments.  
 51
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B CA 
Fig. 2.4.  EGFP localization in MARC-145 cells infected P129-MLU-EGFP-SGR. Confocal 
microscope images showing the localization of EGFP (green) and TO-PRO-3 nuclear staining 
(blue) in MARC-145 cells at 24 hr after infection. Panel C is the merged image. 
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Fig. 2.5. Viral yields of recombinant plasmids. (A) Virus yields from cells transfected with 
pCMV-S-P129 plasmids.  Media was harvested from MARC-145 cells on a 12 well plate at 4 
days after transfection with 2 ug of plasmid DNA.  The amount of virus recovered was measured 
by titration on MARC-145 cells (open bars) and on PAMs (closed bars).  
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Fig. 2.6. Stability of EGFP fluorescence and immunoreactivity.  (A) EGFP fluorescence and (B) 
anti-nucleocapsid staining in the same viral focus in cells infected with Fig. 3. Intracellular 
distribution of nsp2-EGFP. Confocal microscopic images showing co-localization of nsp2-EGFP 
with PRRSV nucleocapsid protein. (A) EGFP expression in MARC-145 cells infected with 
P129-MLU-EGFP.  (B) The same focus stained with Alexifluor-labeled anti-nucleocapsid 
antibody.  (C) A different focus on a duplicate well stained with peroxidase anti-GFP antibody.   
(D) EGFP fluorescence in MARC-145 cells infected with passage 6 of P129-MLU-EGFP-SGR. 
(E) The same focus stained with AlexiFluor-labeled anti-nucleocapsid antibody.  (F) A different 
focus on a duplicate well stained with peroxidase anti-GFP antibody. Photomicrographs were 
obtained at three days after infection with each recombinant virus.  
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Fig. 2.7.  Molecular analysis of EGFP during serial passage of P129-MLU-GFP.  EGFP 
expression was determined by the presence (+) or absence (-) of EGFP fluorescent cells. The 
presence of infection was determined by staining cells with anti-nucleocapsid mAb. Samples 
included media from transfected MARC-145 cells (P0) through the eighth passage (P8). The 
location of primers used for PCR are shown in (B).  The location of mutations in EGFP of a virus 
after five passages in MARC-145 cells is shown in (B). 
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CHAPTER 3 
Nsp2 of porcine reproductive and respiratory syndrome virus; a site for insertion of a 
vaccine deletion marker and virulence attenuation 
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ABSTRACT 
     Vaccines that differentiate infected from vaccinated animals (DIVA) are a new development 
in PRRS vaccine design. The non-structural protein, nsp2, is the single largest viral product and 
plays multiple roles in polypeptide processing and the formation of replication complexes. Using 
reverse genetics and a PRRSV infectious cDNA clone, we constructed several viruses which 
contained deletions and insertions in nsp2. One construct contained a 131 amino acid deletion 
within a relatively conserved region of nsp2. The deleted region was replaced with either green 
fluorescent protein (GFP) or hemagglutinin (HA). The tagged viruses produced normal yields on 
MARC-145 cells and porcine alveolar macrophages. However, gross and micro-histopathology 
showed reduced pathogenesis in pigs. The 131 amino acid peptide, when expressed as a 
recombinant protein and coated onto enzyme linked immnosorbent assay (ELISA) plates, was 
recognized by sera from pigs infected with wild-type virus, but not the deletion mutants. The 
results from this study show that nsp2 is an important target for the development of marker 
vaccines and for virus attenuation.  
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INTRODUCTION 
     Deletion marker vaccines for differentiating infected from vaccinated animals (DIVA) 
provides the means to pursue disease eradication simultaneous with the vaccination of animals 
with modified live virus (MLV) vaccines. Perhaps the best example in the use of a DIVA-based 
vaccine is in the eradication of pseudorabies.  The deletion of the gI or gX of the psuedorabies 
MLV provides for the use of a companion ELISA test to detect ant-gI or gX antibodies, elicited 
in response to infection or exposure to a field virus (28). For small RNA viruses, the creation of a 
deletion marker can be problematic. A limited number of critical genes, overlapping gene 
segments and bi-cistronic reading frames in the genome make deletion or modification of an 
immunogenic region difficult.  
     Infections caused by porcine reproductive and respiratory syndrome virus (PRRSV) are 
responsible for approximately $560 million per year in losses to the U.S. swine industry, making 
it the number one infectious disease in swine. PRRSV belongs to the order Nidovirales and along 
with equine arteritis virus (EAV), lactate dehydrogenase elevating virus (LDV) and simian 
hemorrhagic fever virus (SHFV) form a single family, Arteriviridae.  PRRSV is an enveloped, 
positive polarity, non-segmented, single-stranded RNA virus possessing a 15 kb genome, which 
contains at least 9 open reading frames (ORFs). The coding portion is flanked by 5’ leader and 3’ 
untranslated regions. The genes for the structural proteins occupy the 3’ end of the coding region 
and comprise ORFs 2 through 7 (1, 15). The major structural proteins, glycoprotein 5 (GP5), matrix 
(M) and nucleocapsid (N) are derived from ORFs 5, 6, and 7, respectively (10).  Whereas, GP2a, 
2b, GP3 and GP4, translated from ORFs 2a, 2b, 3 and 4, respectively, are considered minor 
structural proteins whose functions remain unclear, but are required for infection (31).  Based on 
studies of EAV, GP2b, GP3 and GP4 form a heterotrimer associated with the surface of the virion 
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(30).  The ORF2b protein is an integral viral protein and shares similarities with the small 
coronavirus E protein (23, 33, 34). 
     Reverse genetic experiments that produce arterivirus genomes with deletions of single 
structural protein genes have failed to produce viable virus. Therefore, the essential nature of the 
structural proteins makes them unsuitable for construction of a deletion marker virus. Other 
targets for deletion are the nonstructural proteins, which occupy three quarters of the proteome.  
Arterivirus non-structural proteins (nsp’s) are produced by the proteolytic processing of the 
ORF1a and ORF1ab polyproteins, known as pp1a and pp1ab, respectively. Based primarily on 
studies of EAV, the estimated 3,960 amino acid pp1ab protein of PRRSV is processed to yield 
12 products, labeled nsp1-12 (1, 15, 32).  In addition, nsp1 of PRRSV undergoes an autocleavage 
to yield nsp1α and nsp1β.  Both nsp1α and 1β proteins possess papain-like cysteine proteinase 
(PCP) activities (11, 15).  Nonstructural protein 2 (Nsp2) is a multifunctional protein, which, 
after processing, forms the single largest viral protein.  A chymotrypsin-like protease (CP) 
domain, located at the N-terminal end is responsible for the cleavage of the nsp2/3 junction (21). 
In addition,  nsp2 is a co-factor with nsp3-8 in the cleavage of the nsp4/5 junction (29). In EAV, 
the C-terminal region of nsp2 forms a strong non-covalent association with nsp3. It has been 
proposed that the hydrophobic domains in nsp2 and 3 form part of a scaffolding system 
responsible for anchoring the remaining replicase proteins within double membrane vesicles 
(DMVs), which house the replication complexes. The co-expression of EAV nsp2 and nsp3 is 
sufficient to form structures that closely resemble DMV structures (24). The C-terminal end of 
nsp2 also contains several conserved cysteine residues, which may be involved in binding zinc 
(35).  The main protease, nsp4, contains a 3C-like serine protease (SP;22). The cleavage of 
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Glu/Gln and Gly/Ser recognition sites by nsp4 yields the remaining non-structural proteins (1, 
15, 32).  
      The RNA-dependent RNA polymerase (RdRp) and nucleoside triphosphate (NTP)-binding / 
RNA helicase activities are found in the ORF1b proteins, nsp9 and nsp10, respectively (2, 20). 
Nsp11 possesses a NendoU domain with similarities to a poly(U)-specific endoribonuclease, 
XendoU, from Xenopus laevis (25). Nsp12 is a relatively small protein of unknown function.  
        Within pp1ab, nsp2 posses two important properties that make it a potential target for the 
construction of deletion marker virus. First, it is highly immunogenic possessing at least eight B 
cell epitopes. Secondly, field viruses have been identified that contain naturally occurring 
nucleotide insertions and deletions within nsp2. In this paper, using a PRRSV infectious cDNA 
clone, we describe the construction of a virus that contained a 395 nt deletion in nsp2.  
Replacement of the deleted region with GFP or HA in one of the constructs resulted in a live 
virus that replicated in MARC-145 cells and primary cultures of porcine macrophages and 
produced green fluorescence. Nsp2-deleted viruses also replicated in pigs, but possessed an 
attenuated phenotype compared to the parent virus. A recombinant polypeptide corresponding to 
the deleted region was recognized by sera from pigs infected with the intact nsp2 region, but not 
by the sera from pigs infected with the deletion mutants.  Therefore, this study identifies 
deletions in nsp2 which should be useful in the preparation of marker vaccines and for the 
attenuation of virulent isolates.  
 
MATERIALS AND METHODS 
Cells 
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     MARC-145 cells were maintained in MEM with 7% fetal bovine serum (FBS, Amresco) and 
supplemented with pen/strep and funzizone. Porcine alveolar macrophage (PAM) cells were 
obtained from the lungs of four to six week-old pigs by lung lavage with PBS. Cells were plated 
in RPMI with 10% FBS with antibiotics. After two days, cells were infected with virus. 
 
The construction of recombinant PRRSV expressing HA epitope tag. 
     Detailed procedures of the recombinant viruses (pCMV-P129-Mlu-SgrA & pCMV-P129-
Mlu/GFP/SgrA) are described in the Materials and Methods section in Chapter 2.  
     The HA duplex epitope tag having partial Mlu I and SgrAI sites were resuspended in RNase-
Free Duplex Buffer (Integrated DNA Technologies) to 50µM concentration. Heat to 94°C for 2 
minutes, and allowed to cool to room temperature. The resulting product was fully resuspended 
in stable, double-stranded form. The phosphorylated duplex HA epitope tag was ligated into 
5,161bp of Mlu I-SgrAI fragment of pCR2.1-3219▪MluI-4875▪AflII. The Mlu I▪HA▪SgrAI clone 
having intact HA tag was selected by sequence analysis and restriction enzyme digestion. At the 
last step, the 1,305bp Mlu I▪HA▪AflII fragment was ligated into 17,231bp Mlu I-AflII fragment 
of pCMV-S-AflII. The resulting product was pCMV-Mlu▪HA▪SgrA-AflII (Primer lists are in 
Table 1). 
 
Virus preparation and measurement of virus yield 
Recombinant viruses were initially harvested from MARC-145 cells on a 12 well plate at four 
days after transfection with 2µg of plasmid DNA. Viruses were subjected to two more rounds of 
amplication on MARC-145 cells. Passaging was performed by taking a 1:50 dilution of virus and 
placing it on a T-25 flask of confluent MARC-145 cells and harvesting virus three days later. 
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The flask was freeze-thawed prior to harvest. The fourth passage (P4) of the virus was performed 
by infecting six T-75 flasks. After harvest, the virus was  aliquoted into 1ml quantities and stored 
at -80C. This represented the stock virus for inoculation of pigs and other experiments. Virus 
yield was measured by end-point titration of cell culture medium on MARC-145 cells. On the 
day of vaccination, PRRSV stocks were diluted to a concentration of  105 TCID50/ml in culture 
medium and were transported on ice to the research facility. A 4 ml challenge dose of diluted 
stock solution (2 ml per nostril plus a 2 ml intramuscular injection) containing approximately 
4X105 TCID50/ml was delivered to each pig. 
 
Study design and challenge 
Prior to challenge, contact controls assigned to each treatment were removed from the pen and 
housed separately. Contact controls were returned to the group at 4 hrs after challenge. At 
approximately 4 weeks of age (Day 0), 10 randomly allotted pigs from treatment groups T02-
T04 were challenged intranasally (IN) and intramuscularly (IM) as shown in Table 2. The six 
animals allotted to the T01 group received a mock challenge IN and IM. All pigs were restrained 
manually by placing one hand around the snout to limit head movement and the other arm 
around the midsection of the pig. The pigs were challenged IN with a total challenge volume of 2 
ml by instilling 1 ml of challenge material in each nostril. The challenge material was instilled 
drop wise in each nostril in concurrence with an inspiration movement. Pigs were held in a head-
up position for approximately one minute after challenge. Pigs were injected intramuscularly in 
the neck with 2 ml of the same challenge material. 
 
Antibody detection of viral proteins  
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     Detection of antigens in transfected and infected cells was performed by fixing cells for 10 
min in 80% acetone. All antibodies were diluted in PBS with 5% FBS and incubations performed 
for one hr at room temperature. Cells were extensively washed in PBS between incubation with 
primary and secondary antibodies. For detection of HA, the anti-HA mAb (Courtesy of Dr. Park 
Man-Sung, Mount Sinai School of Medicine) was diluted 1:100 in PBS-FBS, followed by 
incubation with FITC-labeled anti-mouse (Rockland).  Viral nucleocapsid antigen was detected 
using SR-30 mAb (a kind gift of Eric Nelson) diluted 1:100 followed by incubation with 
AlexaFluor 584 (Rockland).  GFP was detected using a 1:100 dilution of rabbit anti-GFP 
antibody, prepared against the whole molecule followed by the detection of rabbit antibody with 
peroxidase-labeled goat anti-rabbit.  Peroxidase activity was detected using a DAB staining kit 
(Vector Labs). 
 
Antibody detection of viral antigens in infected pigs 
     Total antibody was measured using the PRRS HerdCheck ELISA (IDEXX).  The results were 
reported as S/P ratio.  Antibodies against the nsp2 protein were detected using an ELISA-based 
method. Each well of a 96-well ELISA plate was coated with 100 ul of protein at a concentration 
of 10 ug/ml per well. Plates were washed with phosphate buffered saline (PBS) and blocked with 
PBS containing 5% goat serum (PBS-GS).  Each serum sample was initially diluted 1:50 in PBS-
GS and then serially diluted 1:2 serial diluted on the ELISA plate. Plates were incubated at 37 °C 
for 1hr and then washed 3x with PBS containing 0.01% Tween 20 (PBST).  Peroxidase-labeled 
rabbit anti swine Ig, diluted 1:1,000, was added to each well and incubated at 37 °C for one hour.  
Wells were washed extensively with PBST and peroxidase activity measured by the addition 
ABTS peroxidase chromagenic substrate (KPL) and plates read at A405. Antibodies against 
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EGFP were detected by indirect fluorescence assay (IFA) against cells that expressed EGFP.  
Since free EGFP leaks out of acetone-fixed cells, Vero cells were transfected with a pEGFP 
plasmid containing EGFP fused to equine infectious anemia virus Rev protein (EGFP-ERev)        
followed by incubation with AlexaFluor 584 (Rockland). Transfection into MARC-145 cells was 
performed on twenty-four well plates using 1 ug of plasmid DNA and LipofectamineTM 2000 
(Invitrogen). Procedures were performed according to the manufacturer’s instructions.  The next 
day and after the appearance of EGFP fluorescence, cells were fixed in 80% acetone for 10 min. 
and then air dried. Pig serum samples, diluted in PBS-GS, were incubated on cells for one hour 
at 37 °C followed by extensive washing with PBS.  Pig antibody was detected with biotin-
labeled goat, diluted in PBS-GS, washed extensively and then incubated with anti-pig followed 
by 1:2,000 dilution of Texas red-labeled streptavidin, diluted in PBS-GS supplemented with 5% 
pig serum. Incubation was continued for an additional 30 min at 37°C. The cells were 
extensively washed with PBS and cells viewed under FITC and rhodamine filters. A positive 
result was identified by the co-localization of EGFP and Texas red staining in the same  cells.  
HA-specific antibody was detected using an ELISA method. ELISA plates were coated with 100 
ul/well of 12 ug/ml, wells were blocked with PBS-GS. Samples were initially diluted 1:10 and 
then subsequent serial 1:2 dilutions.  Plates were incubated for one hr at 37°C then extensively 
washed with PBS.  Peroxidase-labeled rabbit anti-swine Ig, diluted 1:1,000,  was added to each 
well and incubated at 37°C for one hr.  Wells were washed extensively with PBST and 
peroxidase activity measured by the addition of ABTS peroxidase chromagenic substrate (KPL). 
 
Expression and purification of nsp2 (628-759) polypeptide 
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The cDNA fragment corresponding to nucleotides 3219 through 3614 was amplified using the 
forward and reverse primers, SacII 3219F and BamHI 3614R, respectively.  The forward and 
reverse primers contained Sac II and BamHI, for cloning into the SacII and BamHI sites of the 
pHUE expression vector. This vector is designed to express a 5xHis-ubiquitin fusion protein in 
E. coli (6).  The resulting plasmid, pUb-nsp2(628-759), was transduced into BL21(Invitrogen) E. 
coli bacteria. A fresh overnight culture was inoculated into 100 ml of pre-warmed SOB with 50 
ug/ml ampicillin. Bacteria were grown to an A600 value of 0.4-0.6 and then expression of foreign 
protein was induced by the addition of 1 ml of 100 mM IPTG. After 4 hr, the bacteria were 
harvested and the pellet resuspended in 8 ml of binding buffer (10 mM NaPO4, 500 mM NaCl, 5 
mM imidazole, pH 7.4).  1 ml of protease inhibitor cocktail (Biocompare) was added followed 
by 8 mg of lysozyme and the sample placed on ice for 30 min.  The sample was sonicated and 
centrifuged for 20 min at 20,000 x g loaded onto a His GraviTrap Ni column (GE) equilibrated 
with binding buffer. The column was washed with 12 ml of binding buffer and His-tagged 
protein eluted with binding buffer containing 500 mM imidazole, pH 7.4.  Three ml fractions 
were collected and protein-containing fractions identified by SDS PAGE on a 12%  
polyacrylamide gel followed by staining with coomassie blue.  Protein-containing fractions were 
pooled concentrated down to 500 µl on a 20,000 MW cut-off Centricon-Plus filter (Amicon) 
according the manufacturer’s instructions.  
 
RT-PCR detection of EGFP insert  
     The presence of the EGFP insert was detected by reverse transcription-polymerase chain 
reaction (RT-PCR) amplification using total RNA from sera infected with P129-GFP. Total 
RNA was isolated from cells using TRIzol, (Invitrogen). The primers chosen for RT-PCR 
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amplification flanked the EGFP insert. The sequence of the 2941F and 3816R forward and 
reverse primers were 5’-AGCCAATTTTTGTGTCTGCACTGCAACACAAATTT-3’ and 5’–
GCAACGGCCCCCCACCGGCCGCATCTACGCCGTCTG-3’, respectively. 
Viral RNA was reverse transcribed using SuperScript III (Invitrogen) and the reverse primer. 
Amplification was performed using TaKaRa Ex TaqTM according to the manufacture’s 
recommendations. Reaction conditions included an initial denaturation step of 95˚C for 60 
seconds followed by 30 cycles of 94˚C (35 sec), 58˚C annealing (35 sec), and 72˚C extension (1 
min). The reaction was concluded with a 10-minute incubation at 72˚C. PCR products were 
separated on an agarose gel and stained with ethidium bromide. For sequencing products were 
cloned into pCR2.1 (Invitrogen) and amplified in Top10 E. Coli cells.  Minipreps of overnigh 
cultures were prepared using Wizard DNA purification kit (promega).  Sequencing was 
performed using by ACGT.Inc, Chicago 
 
RESULTS 
In vitro properties of nsp2 deletion viruses 
     Site-directed mutagenesis was used to introduce unique Mlu I and SgrAI restriction enzyme 
sites at nucleotide positions 3,219 and 3,614, respectively, of ORF1a in the pCMV-S-129 cDNA 
infectious clone. This clone does not require the in vitro transcription step of RNA prior to 
transfection, but incorporates a cytomegalovirus (CMV) promoter for the transcription of full-
length viral RNA by cellular RNA pol II  The restriction sites were created without changing the 
peptide sequence. Furthermore, the region covered by the Mlu I and SgrAI is a relatively 
conserved region that covers a portion of nsp2 between hypervariable regions HV-1 and HV-2 
(Fig. 3.1).  The Mlu-SgrA region is well-removed from the N- and C-terminal domains essential 
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for nsp2 function.  The deleted region, located between the Mlu I and SgrAI sites, was replaced 
with either a 798 bp EGFP cDNA or the much smaller 24 bp HA tag,YPYDVPDY. Viruses 
derived from transfected MARC-145 cells were further amplified by performing four additional 
passages on MARC-145 cells.   
     EGFP fluorescence appeared within 8 hr after infection with the P129-EGFP virus.  
Fluorescence was predominantly perinuclear and co-localized with the N protein, two 
localization properties consistent with the intracellular distribution of nsp2 (referred to in 
Chapter 4).  The HA peptide was not detected in cells after infection with the P129-HA virus or 
after transfection with the P129-HA plasmid. Similar results were obtained from viruses and 
infectious viral cDNAs that expressed the FLAG peptide.  The transfected cells supported virus 
replication as demonstrated by the presence of positive staining with antibodies to PRRSV N. 
The reason for the absence of peptide tag antibody recognition is unclear, but is a likely related 
to the location of the tag within nsp2.  The conformational folding of the protein may embed the 
peptide tag within the native protein, making it inaccessible to antibody.  
    Recombinant viruses were tested for replication on MARC-145 and porcine alveolar 
macrophage (PAM) cells.  PAMs are primary cells derived from lung lavage of young pigs and 
are one of the naturally occurring cell populations that support virus replication in the pig.  The 
P129-GFP virus and the parent wild-type P129 virus, containing the Mlu-SrgA restriction sites, 
replicated to similar levels in MARC-145 cells; consistently achieving yields of 7 log TCID50/ml 
of media, which are similar to yields obtained for wild-type viruses isolated from infected pigs. 
In contrast, the P129-HA virus produced an approximate 2 log reduction in yield. However, the 
continued passage of P129-HA for an additional three times increased the yield to that of the 
P129-GFP and P129 viruses.  
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Experimental infection of pigs  
 P129 (passage five), P129-GFP (passage five) and P129-HA (passage eight) viruses were used 
to infect pigs.  The P129 inoculum was derived from the infectious clone that contained the Mlu 
I and SgrA I restriction enzyme sites. Groups of 10 PRRSV-negative four week old pigs were 
infected with 5 logTCID50 of each virus using a combination of intranasal and intramuscular 
administration. Besides the three virus-infected groups, an additional group contained six mock-
infected pigs, which received only tissue culture medium. By four days after infection, pigs in 
the P129 group showed outward signs of PRRS, including respiratory distress and lethargy. The 
other groups exhibited no change in behavior.  At ten days after infection, half the pigs from 
each group were sacrificed and lungs examined for gross and microscopic changes.  Compared 
to the mock-infected pigs, the lungs from the five P129 pigs appeared heavy with a wet 
appearance, anatomical changes characteristic of acute PRRS. Representative photomicrographs 
of lungs from infected and control pigs are shown in Figure 3.2. At the microscopic level, the 
lungs from the P129 pigs also exhibited features characteristic of acute PRRS, including 
collapsed alveoli with infiltration of macrophages and accumulation of immature lymphocytes in 
the interstitium. The P129-HA pigs showed few gross or microhistological changes and appeared 
similar to the lungs from the mock-infected group.  At the microscopic level, the lungs from the 
P129-EGFP pigs possessed only a few areas of patchy interstitial pneumonia.   
      Serology and virus isolation were used to determine if the PRRSV pigs were productively 
infected. We used a commercially available ELISA test to determine the antibody responses in 
virus and mock-infected pigs.  When used for the measurement of antibody in field samples, a 
0.4 S/P ratio value is used as the cutoff value for identifying a pig as having a 95% probability of 
being seropositive for PRRSV. Because of the low  background values for the mock-infected 
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pigs, we increased this cutoff value to an S/P ratio of 1.0.   The results showed that all pigs 
produced antibody to PRRSV, whereas the mock-infected pigsremained seronegative throughout 
the study. Antibody responses of pigs retained for the full 28 days of the experiment are shown 
in Fig. 3.3. Typical of the immunological response following PRRSV infection, antibody levels 
showed a wide degree of variation. Because of this variation, it was not possible to make 
accurate quantitative comparisons of antibody responses between the groups of infected pigs.  
However, there appeared a qualitative difference between the P129 and P129-HA groups. At 10 
days after infection, all five P129 pigs possessed PRRSV antibodies compared to no pigs in the 
P129-HA group. These data indicate that the antibody response to the P129-HA virus was 
delayed.  
     At four hours after challenge, two naïve, PRRSV-negative control pigs, were placed in each 
virus group and allowed to intermingle with the other challenge pigs during the remainder of the 
experiment. These contact control pigs were used as a means to detect the presence of virus shed 
by infected pigs. Sources of shedding include contact with the innoculum used for challenge or 
from virus shed after the onset of viremia in the challenge pigs. Pigs typically become viremic 
two to three days after challenge. All contact control pigs seroconverted demonstrating that virus 
was being shed.  In the P129 group, seroconversion was evident at day 10, which was three days 
after the appearance of antibody in the challenge pigs.  Therefore, infection of the contact pigs 
was the likely result of virus shed from viremic pen mates.  Seroconversion of the contact control 
pigs in the P129-HA and P129-GFP groups followed a similar pattern, indicating that infection 
was the result of shedding from viremic pigs.   
     Virus replication was also assessed by virus isolation (VI) from serum.  The results presented 
in Fig. 3.4A show that all 10 pigs in the P129 group were VI positive by 10 days after infection.  
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Virus was recovered from 8 of 10 P129-GFP and 8 of 10 P129-HA pigs. Virus was recovered 
from sera of all contact control pigs. The last VI-positive serum sample in the P129 group was 
obtained at 14 days after infection. In contrast two of five pigs in the P129-HA group were still 
VI positive at 21 days. The contact control pigs became VI-positive after the challenge pigs, 
consistent with the shedding of virus by the acutely infected challenge pigs.  
     The amount of virus in each serum sample was assessed by measuring the TCID50/ml of 
virus. Mean logTCID50/ml values for all virus challenge pigs are shown in Fig. 3.4B.  Similar to 
the antibody results, there was a wide variation between pigs within each group.  Generally, the 
P129 pigs achieved higher levels of virus in the blood with the peak levels of 3.5 logTCID50/ml, 
at Day 7 after infection. This was compared to mean values of approximately 1.0 logTCID50/ml 
for the P129-GFP and P129-HA groups.  Even though the amount of virus recovered from sera 
was lower, the P129-HA and P129-GFP groups appeared to sustain detectable levels of virus for 
a longer period compared to the P129 group.  Collectively, these data indicated that the P129 
pigs attained a higher level of viremia.  Even though the peak level of viremia in the P129-HA 
group was lower, viremia was extended for a longer period of time. 
 
Antibody recognition of nsp2 (628-759), HA and GFP tags 
The peptide sequence corresponding to amino acids 628-759 of P129 nsp2 is shown in Fig. 3.5A.  
For the purpose of comparison, we included the peptide sequence from VR-2332, a different 
isolate and widely regarded as the prototypic example of North American Type 2 PRRSV 
isolates. There are 19 amino acid differences (86% identity) between the two viruses. Analysis 
for the presence of B cell epitopes predicted to be immunogenic was performed using the web-
based computer program, Antigenic (EMBOS). The results showed seven oligopeptide regions 
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which can potentially function as B cell epitopes.  Recently, Lima et al., conducted an antibody 
pepscan analysis of the PRRSV proteome. The approach was to screen a set of oligopeptides 
prepared from PRRSV isolate NVSL 97-7895 (GenBank accession no. AY545985) against 
antibodies from pigs infected with the 97-7895 virus as well as pigs infected with other isolates.  
The results showed several linear epitopes within nsp2,  including the region covered by amino 
acids 756-770 in nsp2 of isolate 97-7895 or amino acids 749-763 in P129 (see peptide sequence 
in Fig. 3.5A surrounded by a dashed line box). The cDNA corresponding to the nsp2 (628-759) 
peptide of P129 was cloned into pHUE (6) to create the construct pHUE-nsp2(629-759).  Four hr 
after induction with IPTG, the bacteria expressed the peptide corresponding to the nsp2-ubiquitin 
fusion protein (see Fig. 3.5B).  The 5xHis-ubiquitin-nsp2 fusion protein was extracted using 
native conditions, affinity isolated on a Ni-sepharose column, concentrated and coated onto wells 
of 96-well ELISA plates. Serum from PRRSV infected pigs was incubated with the immobilized 
peptide and bound antibodies detected using a peroxidase-labeled anti-pig secondary antibody. 
Sera from pigs infected with VR-2332 recognized the P129 nsp2(628-759) peptide (data not 
shown). The P129 nsp2 peptide was incubated with sera from pigs at 28 days after infection with 
P129, P129-HA and P129-GFP viruses.  When compared to mock-infected pigs, four of the five 
pigs in the P129 group showed elevated A405 values. These values were also elevated compared 
to the other virus-infected pigs. We then measured reactivity of the 28 day serum samples against 
HA and EGFP antigens.  Measurement of anti-HA antibodies was performed using a modified 
ELISA.  There was no evidence of reactivity against HA using sera from P129-HA (data not 
shown). We also determined if pigs infected with P129-EGFP made antibodies against EGFP.  
The experimental approach was to incubate dilutions of sera with cells at 24 hr after transfection 
with a construct that expressed an EGFP-protein fusion protein.  Since free EGFP rapidly leaks 
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out of cells, we incorporated a construct that expressed EGFP fused to an EIAV Rev protein.  
EGFP-reactive antibody was detected using AlexaFluor 584-labeled anti-pig antibody. A 
positive result was the localization of red and green fluorescence in the same cells. At dilutions 
of less than 1:100 there was no reactivity of mock-infected or P129-infected  pigs against the 
fusion protein (data not shown).  End point titrations for sera from P129-EGFP pigs ranged 
between 1:100 and 1:800. These data show that pigs infected with P129 made antibodies against 
the nsp2(628-759) peptide and peptide-specific antibody was absent in pigs infected with viruses 
that lacked the peptide region. Furthermore pigs infected with P129-EGFP made antibodies that 
recognized EGFP.  The absence of anti-HA antibodies in P129-HA pigs is consistent with the 
inability of anti-HA antibody to detect HA in cells after transfection with the infectious clone 
and after infection of cells with P129-HA.  We assume that the small HA epitope is hidden 
within nsp2 and inaccessible to antibody. 
 
Stability of EGFP expression during infection 
     Viruses isolated from the sera of the P129-EGFP-infected pigs were propagated on MARC-
145 cells. The isolated viruses were no longer fluorescent.  However, immunocytochemical 
staining using anti-GFP antibody indicated that at least a portion of the EGFP protein was still 
being expressed. An example of a P129-EGFP virus showing a negative fluourescence but 
positive for anti-GFP staining is shown in Fig. 3.6A. The retention of EGFP immunoreactivity is 
consistent with the stimulation of an anti-GFP response in pigs.  Forward and reverse nsp2-
specific PCR primers were chosen that flanked the 5’ and 3’ ends of the EGFP insert.  Of the 
four isolates, two produced PCR products. The absence of products could be due to loss of the 
region containing the primer sequence.  The PCR-negative viruses were not subjected to further 
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investigation. The RT-PCR amplification of the other two viruses produced three products. The 
results showed that product 3 and product 4B possessed an intact EGFP insert, but there were 
four mutations in product 4B and one mutation in product 3, respectively (Fig.3.6C and D).  
Product 3 had a Tyr to Ser change at position 66 and product 4B had a Met to Val change at 
position 89, a Arg to Cys at position 96, a Val to ala at position 151 as well as a mutation at 
position 66. Product 4A possessed a deletion in EGFP between amino acids 32 to 266 . There 
were no mutations in the region of the cDNA product flanking the EGFP insert. 
 
DISCUSSION  
     A major shortcoming of current PRRSV vaccines is the inability to discriminate vaccinated 
pigs from pigs infected with field isolates. Another limitation in the use of modified live vaccine 
(MLV) is the potential for reversion into a virulent form, which has been reported to occur in the 
field (26). The effort to find marker PRRSV viruses is hampered due to the compact arterivirus 
genomic structure, such as overlapping and bicistronic ORFs. The development of PRRSV 
reverse genetic system makes it possible to introduce mutations to delineate essential and 
nonessential domains. Nsp2, the largest single processed protein produced during infection is 
predicted to be approximately 980 amino acids. This size may be smaller or larger based on 
which cleavage sites are used, the presence of insertions and deletions and the genotype of the 
PRRSV isolate. Genetic sequence comparisons of nsp2 peptide from several PRRSV isolates 
identify at least two hypervariable regions, which naturally incorporate nucleotide insertions and 
deletions (Fig.3.1A). Mlu I and SgrAI restriction enzyme sites were introduced at nt position 
3219 an 3614 of nsp2, in the pCMV-S-P129 cDNA infectious clone by site-directed 
mutagenesis. The 395nt deleted region, located between the two enzyme sites, was replaced with 
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798bp EGFP or a much smaller 24 bp HA tag (Fig.3.1A). Virus yields measured just before 
infection had 5.5 log TCID50 in all three viruses and specially, P129-HA virus had three 
additional passages for cell adaptation and enhancing titration. After infection with recombinant 
viruses, the P129-HA virus, which had virus yield similar to that of P129 in vitro, showed few 
gross or microhistological changes and appeared similar to the lungs from mock infected pigs. 
The deletion of the relatively conserved 395bp domain located between 3219 and 3614 in nsp2 
of ORF1a may play a pivotal role in virulence and contributed to the attenuation in vivo. Other 
approaches were performed to make several different marker viruses, which included an 
extensive deletion of hypervariable regions of nsp2, but only HA tagged virus was recovered. 
Logically, HV domains incorporating deletions and insertions should be dispensable for viral 
replication but it is postulated that they have critical motifs necessary for viral functionality. For 
example, HV-2, which is connected with transmembrane region, acts as a scaffolding protein for 
replication complex formation and the disruption of that domain would have a lethal effect on 
viral replication. 
     Virus replication was measured by virus isolation (VI) from serum. In Fig.3.4, the P129 group 
all had VI positive sera, other two groups had 8 of 10 VI positive, but VI positive samples of 
P129-HA group could be detected by 21 days infection. All contact controls were also positive 
and these data strongly support the conclusion that acutely infected pigs were shedding virus, 
and is consistent with the result of seroconversion of naïve contact controls. 
     Quantitative measurement of VI positive samples showed that P129 had the peak levels of 3.5 
logTCID50/ml but other two groups showed two fold below peak, but virus yield of P129-HA 
could be detected and sustained its viremic condition for a longer period of time. This data 
indicated, naturally occurring deletion of nsp2 of PRRSV could support viral replication, but 
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affected an attenuation and maintained a persistent infection in pigs (3, 19). Type 1 North 
American PRRSV strain with a broad nsp2 variability had a relatively low pathogenesis in 
experimental condition (12, 13), suffice it to say that the reason of low pathogenesis of HA virus 
could be associated with the deletion of nsp2 region.   
     The cDNA corresponding to the nsp2(628-759) peptide of P129 was expressed as 5X his-
ubiquitin fusion protein four hr after induction with Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (6, Fig.3.5B) and it had seven putative B cell epitopes and another linear epitope site 
which was derived from NVSL 97-7895 PRRSV isolate (GenBank accession no.AY545985, 
Lima) (Fig.3.5A). With 131 amino acid nsp2 peptide ELISA, antibody reactivity was measured 
and when compared to mock-infected pigs, four of the five pigs in the P129 group showed 
elevated A405 values (Fig.3.3). The result of reactivity of the 28 day serum samples against HA 
and EGFP showed low A405 values compared to P129 (Fig.3.3). This data showed that pigs 
infected with P129 made antibodies against the nsp2 (628-759) and antibody was absent in pigs 
infected with viruses that lacked the peptide region.  It can open a way for a possibility of 
PRRSV DIVA vaccine, in order for the accurate evaluation, more field samples should be tested 
and the standard cut off value be determined. 
     Another experimental approach was made if P129-EGFP can produce antibodies against 
EGFP. Serum samples from 28 days after infection in P129-EGFP group showed an 
immunoreactivity against EGFP fused to an EIAV Rev protein (Fig.3.3). But, the detection of 
anti-HA antibodies using sera from P129-HA group was failed. This is consistent with the 
inability of anti-HA antibody to detect HA in cells after transfection with infectious clone and 
after infection of cells with P129-HA. The peptide tags embedded within nsp2 prevent antibody 
from recognizing them due to folded native condition. 
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     Viruses isolated from sera of the P129-GFP was grown in the MARC145 cell, it had no 
fluorescence but supported viral replication and retained immunoreactivity against EGFP 
(Fig.3.6A). To characterize which motifs could affect negative GFP fluorescence, PCR analysis 
was performed with two primers flanking the 5’ and 3’ ends of the EGFP insert. The GFP non-
fluorescent clones showed the mutations in Tyr-66 located in chromophore and Arg-96 known to 
participate in the formation of the Tyr-66/Gly-67 ring structure (Fig.3.6D) (8, 17). An Arg-96 
mutation of product 4B were also found at P129-MLU-GFP passage 5 in vitro study (refer to 
chapter II Fig.2.7B and Fig.3.6D). It was the similar result both in vitro and in vivo and the first 
report of finding mutations that make EGFP non-fluorescent during in vivo study (refer to 
chapter II discusstion). In product 4B, a Met to Val change at position 89 and Val to Ala change 
at position 151 were also discovered but, whether they had a negative effect on EGFP 
fluorescence, remains to be determined. 
    With the advent of PRRSV reverse genetics system, the development of attenuated marker 
vaccine armed with function of a DIVA was not an impossible dream. In this study, we opened a 
tangible road in PRRSV research field for the first time. Together with the instability of huge 
nsp2 domain, newly emerging PRRSV quasispecies could be a big barrier for setting up an 
effective DIVA system. But, relatively conserved and immunogenic nsp2 395bp region will not 
be easily subject to attack of negative pressure willing to modify its genotype. For the future 
study, a challenge study against highly virulent PRRSV isolate should be accompanied and 
except nsp2, the effort of finding conserved but nonessential domains which could be a different 
selection marker is to be made. 
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Table 3.1a- Primers used for introducing AflII site in nsp3 of pCMV-S-129 
 
AflII (4856-4900) 
Forward 5’ CTTTGCCCAGCTGAATGGACTTAAGATCAGGCAAATTTCCAAGCC 
Reverse 5’ GAAACGGGTCGACTTACCTGAATTCTAGTCCGTTTAAAGGTTCGG 
(Bold and underlined nucleotide is mutated one, Original one is A. Box indicates AflII) 
 
 
 
 
Table 3.1b- Primer lists used for site-directed mutagenesis 
 
3219 MluI F    5’ ACGCGTCCAAAATACTCAGCTCAA       
3614 SgrAI R 5’ CACCGGTGTTTTCTATTTTCCCGAG      
3614 SgrAI F 5’ CACCGGTGAGATGATCAACCAGGGA 
4875 AflII R 5’ CTTAAGTCCATTCAGCTGGGCAAA 
(Underlined nucleotide is indicated restriction enzyme sites) 
          HA tag F      5’ CGCGTATACCCATACGACGTCCCAGACTACGCA  
          HA tag R      5’ CCGGTGCGTAGTCTGGGACGTCGTATGGGTAT 
          (Bold and underlined nucleotide was phosphorylated to increase ligation efficiency) 
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Table 3.2. 
 
TX Virus Passage Challenge Route # of pigs 
NT1# NA NA NA 6 
NT2# NA NA NA 6 
T01 MOCK NA IN/IM 6 
T02 P129-HA 8 IN/IM 10 
T03 P129-GFP 5 IN/IM 10 
T04 P129-Mlu-SgrA 5 IN/IM 10 
#NT1 pigs serve as sentinel animals to monitor the health status of source pigs. NT2 pigs will 
serve as contact controls for challenge groups, two per room for groups T02 thru T04. IN = 
intranasal, IM = intramuscular 
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Fig.3.1 (A) Hypervariable regions in nsp2 and the construction of recombinant PRRS viruses. 
Hypervariability regions, HV-1 and HV-2, were identified by comparing the peptide sequences 
of 14 North American isolates, which were obtained from GenBank. Nsp2 peptide sequences 
were aligned using Clustal-X. The histogram shows the number of amino acid substitutions 
along the nsp2 peptide sequence. Each bar covers 10 amino acids. The bottom figure shows the 
recombinant viruses that were used for pathogenesis study. The last construct contains a 27 nt 
insert containing the HA peptide. (B) Viral yields of recombinant viruses. Virus yields from cells 
transfected with three recombinant plasmids.  Media was harvested from MARC-145 cells on a 
12 well plate at 4 days after transfection with 2 ug of plasmid DNA.  The amount of virus 
recovered was measured by titration on MARC-145 cells (open bars) and on PAMs (closed 
bars).  
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Fig.3.2 Photomicrographs of lungs from infected and control pigs. 10 days postinfection, 5 pigs 
from three groups infected with recombinant viruses (P129-MluI-SgrAI, P129-HA, P129-EGFP) 
were examined for histopathology. 
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Fig.3.3 Antibody detection of viral antigens in infected pigs. Total antibody was measured using 
the PRRS HerdCheck ELISA (IDEXX).  The results were reported as S/P ratio.  Antibodies 
against the nsp2 protein were detected using an ELISA-based method. Closed circle is antibody 
response using herdcheck ELISA kit and open circle indicate A405 value using the nsp2 (628-
759) peptide ELISA. Closed rectanglar are the antibody response of contact control placed in 
each virus group and allowed to intermingle with the other challenge pigs. In PRRSV-GFP, open 
triangle shows GFP reactivity against cells transfected with EGFP-ERev. 
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Fig.3.4 (A) Virus isolation from infected pigs sera. Black bars represent the number of VI 
positive pigs and shaded bars are contact control pigs placed four hour after infection. (B) The 
amount of virus in each serum sample. The virus yield was measured by logTCID50/ml. Closed 
circles are the amount of virus from sera infected with P129, closed rectangles are from sera 
infected with P129-GFP, and closed triangles are from sera infected with P129-HA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 89
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VR-2332 
P129 
VR-2332 
P129 
759 
A. 
B. 
628 
50 
 
37 
 
25 
 
20 
M      1      2      3      4   
5xHis-Ub-nsp2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.5 Expression and purification of nsp2(628-759) peptide. (A) The above peptide sequence 
shows the region deleted in the cloned construct PRRSV-▲-GFP, which was derived from the 
pCMV-S-P129 infectious clone.  (B) The cDNA corresponding to this region was cloned into 
pHUE and expressed as a His-tagged ubiquitin fusion protein (6). Four hr after induction with 
IPTG, the bacteria expressed the peptide corresponding to the nsp2-ubiquitin fusion protein. 
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Fig.3.6 (A) Stability of EGFP fluorescence and immunoreactivity. EGFP fluorescence and anti-
nucleocapsid staining in the same viral focus in cells infected with GFP-negative sera. (B and C) 
Molecular analysis of EGFP negative and VI positive sera. 2941F and 3816R primer sets 
flanking EGFP were used for RT-PCR analysis of four isolates. (D) The amino acids change and 
deletion of EGFP from isolate number 3 and 4.  
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CHAPTER 4 
Subcellular localization properties of porcine reproductive and respiratory syndrome virus 
non-structural proteins. 
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ABSTRACT 
          Infection of cells with the prototype arterivirus, equine arteritis virus (EAV), involves the 
formation of replication complexes in association with ER membranes in the perinuclear region 
of the cell.  However, there are examples of arterivirus proteins that localize to other intracellular 
compartments, such as the nucleus. The purpose of this study was to characterize the intracellular 
localization properties of the non-structural proteins (nsp’s) of porcine reproductive and 
respiratory syndrome virus (PRRSV). Confocal microscopy of individually expressed enhanced 
green fluorescent protein (EGFP)-labeled fusion proteins identified nsp 2, 3, 9 and12 as 
predominately cytoplasmic. Nuclear accumulation was observed for nsp 1, 4, 7, 10 and 11. The 
main replication complex scaffolding proteins, nsp2 and 3, did not co-localize with anti-Golgi or 
anti-calnexin (endoplasmic reticulum marker) antibodies. Nsp2, when expressed as an EGFP-
tagged protein by a recombinant PRRS virus, also failed to co-localize with endoplasmic 
reticulum (ER), Golgi and lysozomal associated membrane protein-1 (LAMP-1). Even though 
this study did not identify the membrane compartment associated with PRRSV nsp localization, 
these results suggest that there may be some flexibility among the arteriviruses in the source of 
the membranes recruited in the formation of replication complexes. 
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INTRODUCTION 
     Porcine reproductive and respiratory syndrome virus (PRRSV) is responsible for reproductive 
failure and respiratory disease in neonatal pigs. PRRSV is a member of the family Arteriviridae, 
which also includes equine arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDV), 
and simian hemorrhagic fever virus (SHFV) (1).  The Arteriviridae, Coronaviridae and 
Roniviridae belong to a single order, Nidovirales (2). The common feature within the nidovirus 
group is the formation of a 3’ co-terminal nested set of subgenomic mRNAs, which possess a 
common leader and a poly-A-tail (3). 
        The localization properties of arterivirus proteins are associated with functions related to 
virus replication, virion assembly/budding, and escape from host cell defenses. During EAV 
replication, all nsp’s localize to the perinuclear region and are associated with DMVs, which are 
derived from ER membranes.  The staining of EAV-infected cells with antibodies against the 
ER-associated protein, PDI, shows co-localization with antibodies prepared against the 
individual nsp’s (8).  In addition, nsp1 is also found in the nucleus (9).  The N proteins of EAV, 
PRRSV and several coronaviruses also localize to the nucleus during infection and when 
expressed as GFP-labeled proteins (10, 11, 12). Presumably, nuclear localization of structural 
and non-structural proteins is involved in the control of nuclear processes during virus 
replication (9, 10, 12).  
     One important limitation in the study of the subcellular localization of nsp’s in live virus 
systems is that antisera prepared against an individual nsp also cross-reacts with the much larger 
parental polyproteins and/or with complexes incorporating other structural and non-structural 
proteins. The purpose of this study was to follow the localization properties of the PRRSV nsp 
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products expressed as individual nsp’s tagged with enhanced green fluorescent protein (EGFP) 
and EGFP-nsp2 fusion protein expressed by recombinant PRRSV. 
 
MATERIALS AND METHODS 
Virus and Cells 
     Vero and MARC-145 cell lines were maintained in Dulbecco’s modified minimal essential 
medium (DMEM) supplemented with 8% fetal bovine serum, 0.008% Fungizone and 0.01% 
penicillin-streptomycin.  The MARC-145 cell line, a derivative of MA-104 cells [32], was used 
in those experiments involving PRRSV-infected cells. Because of relatively poor transfection 
efficiencies in MARC-145 cells, experiments involving nsp cDNA expression incorporated the 
use of Vero cells.  
 
nsp plasmid construction 
      The forward and reverse primers for PCR amplification and cloning of the individual nsp2 
regions, shown in Fig. 4.1, are listed in Table 4.1. PCR and cloning was done by standard 
recombinant DNA techniques. Restriction sites were added to the 5′ ends of the respective sense 
and antisense PCR primers. For cloning the individual nsp products, total RNA was isolated 
from MARC-145 cells at 48 hr after infection with North American PRRSV isolate SD2393 
using a QIAamp viral RNA kit (Qiagen).  cDNA for PCR was prepared by reverse transcription 
using Superscript II (Invitrogen) and random hexamer oligonucleotide primers and according to 
manufacturer’s recommendations.   PCR amplification was performed using pfu polymerase 
(Stratagene) in a reaction volume of 100 µl containing Mg-free 1x PCR buffer, 2 mM MgCl2, 
200 µM of each dNTP, 1µM of each primer and 2.5 units of polymerase and 2 µl of template.  
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PCR conditions for all reactions consisted of 1 cycle of 95 0C for 2 min, 35 cycles at 94 0C for 30 
seconds, 55-60 0C for 30 seconds, 68 0C for 1 min per kb pair. A final extension was performed 
at 70 0C for 10 min.  PCR products were double-digested with appropriate restriction enzymes 
and ligated in-frame into pEGFP-C3 (Clontech Inc). Plasmid constructs were amplified by 
transformation into E. coli TOP 10F cells (Invitrogen). Plasmid DNA for transfection was 
prepared using a Wizard miniprep kit (Promega). All constructs were sequenced prior to use. 
      The transfection of plasmid DNA into Vero cells was performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Even though MARC-145 cells support 
PRRSV infection, Vero cells were transfected with a higher efficiency. Approximately 24 hours 
prior to transfection, 2 X 105  Vero cells were seeded into each well of a 12-well plate. Cells 
were transfected with 2 µg of plasmid DNA. One day after transfection, the cells were viewed 
under a fluorescence microscope and EGFP expression detected using a FITC excitation filter. 
 
Immunoblot detection of EGFP-labeled proteins and immunofluorescence 
microscopy  
     For immunoblot analysis of expressed proteins, transfected cells on a 12-well plate were lysed 
with 100ul of 2X Laemmli sample buffer, boiled for five minutes, then separated using SDS-
polyacrylamide gel electrophoresis under reducing conditions. Proteins were transferred onto a 
nylon membrane. Membranes were blocked at room temperature for 1 hr in 5% nonfat dry milk 
in PBS with 0.2% Tween-20 (PBST). After three washes with PBST, affinity-purified anti-GFP 
antibody (Rockland) was diluted 1:1,000 in blocking buffer and incubated with the membrane 
for one hr at room temperature (RT). Membranes were washed three times for 15 minutes at RT 
with Tris-buffered saline containing 0.2% Tween-20 (TBST). Rabbit anti-goat horseradish 
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peroxidase-conjugated antibody (Rockland) was diluted 1:1,000 in blocking buffer and incubated 
with membranes for 1 hr at RT followed by three 15 min washes with TBST. Peroxidase activity 
was detected using Supersignal West Pico chemiluminescent substrate (Pierce) and membranes 
were exposed to Kodak autoradiographic film. 
     For immunofluorescence confocal microscopy, coverslips of transfected cells were washed 
with PBS, fixed for 10 minutes with 2% paraformaldehyde in PBS, and then stained with 
antibodies against ER-localized protein (calnexin; mouse mAb AF18 from Abcam, PDI; mouse 
mAb 1D3 from MBL), Golgi localized protein (mAb 371-4 from Abcam) or LAMP-1 (CD107a; 
mouse mAb H4A3 from BD Pharmingen), or PRRSV N protein (mAb SDOW-17; courtesy of 
Eric Nelson, South Dakota State University). Mouse antibodies were detected with goat anti-
mouse IgG conjugated with AlexaFluor 594 (Molecular Probes). All antibodies were diluted 
1:500 in blocking buffer (PBS containing 3% normal goat sera and 0.2% saponin) and 
incubations performed for 1 hr at RT followed by extensive washing in PBS. In some 
experiments, cells were counterstained with the nuclear stain TO-PRO-3, diluted in blocking 
buffer. Coverslips were mounted and viewed using a Zeiss LSM 510 confocal microscope.  
 
Construction of nsp2-EGFP expressing PRRS virus 
     A unique Mlu I site was inserted into nucleotide position 3,219 nt in ORF1a of the infectious 
cDNA clone pCMV-S-P129 (21) using a QuikChange II XL Site-Directed Mutagenesis Kit 
(Stratagene).  The EGFP gene of pEGFP-C3, minus the stop codon, was PCR amplified using 
primers with Mlu I sites on both ends and cloned into pCR2.1. (Invitrogen). The EGFP fragment 
was removed by cutting with Mlu I and then ligated into the Mlu I site of pCMV-S-P129 to yield 
the plasmid pCMV-S-P129-nsp2-EGFP. The correct insertion of EGFP was determined by DNA 
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sequencing. The plasmid was transfected into MARC-145 cells to produce the virus P129-nsp2-
EGFP.  
 
RESULTS 
Immunoblot detection of pp1ab EGFP fusion proteins expressed in Vero cells 
    The cloned nsp products, based on the cleavage sites shown in Fig. 4.1 for SD-23983, a typical 
North American Type 2 PRRSV isolate, included nsp1 (383 amino acids), nsp2 (980 amino 
acids), nsp3 (446 amino acids), nsp4 (204 amino acids), nsp5 (170 amino acids), nsp7 (259 
amino acids), nsp8 (45 amino acids), nsp9 (640 amino acids), nsp10  (441 amino acids), nsp11 
(224 amino acids) and nsp12 (152 amino acids). The only construct not made was nsp6, which 
was predicted to be only 16 amino acids in length. In all constructs, EGFP was fused to the N-
terminal end of the nsp. Because antibody reagents were not available for the detection of the 
individual PRRSV nsp products in Western blots, the fusion proteins were detected using a 
polyclonal anti-GFP antibody.  Nearly all proteins were detected on immunoblots (Fig. 4.2). The 
only exceptions were nsp2, nsp5 and nsp8. The EGFP-nsp2 fusion protein was easily detected by 
fluorescence after transfection of Vero cells with the pEGFP-nsp2 plasmid, but was not detected 
when lysate proteins were transferred to nylon membranes. The negative immunoblot result may 
have been due to inefficient transfer of the large fusion protein to be efficiently transferred to the 
nylon membrane. The removal of 280 amino acids from the C-terminal end of nsp2 resulted in 
the truncated protein, EGFP-nsp2*, which was easily detected in Westerns (Fig. 2). The 
localization properties of EGFP-nsp2* in transfected Vero cells were the same as the full length 
GFP-nsp2 construct. The anti-GFP antibody frequently identified minor bands that were smaller 
than EGFP-nsp2* (see arrow in Fig. 4.2).  These smaller products may represent cleavage 
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products that result from the action of cellular proteases.  EGFP-nsp5 and 8 proteins were not 
detected in Westerns or by fluorescence microscopy in transfected cells.  We assumed that these 
constructs were either unstable or lethal when expressed in Vero cells. Except for nsp1, the 
remaining EGFP-nsp fusion proteins migrated at their predicted sizes (Fig. 4.2).  The intact 
EGFP-nsp1 product was predicted to migrate at approximately 71 kDa. The appearance of a 
smaller product on Western blots was consistent with the cleavage of nsp1 into 1α and 1β 
products (13). The size of the EGFP-labeled nsp1 protein, which migrated at approximately 45 
kDa, was consistent with the successful autoproteolytic cleavage between residues C126 -R127. 
Because the EGFP tag is located on the N-terminal end of nsp1, we assumed that only the nsp1α 
product was being detected in Westerns. This result indicates that the attachment of EGFP does 
not interfere with the autoproteolytic activity of nsp1.   
 
Subcellular localization of EGFP- nsp’s 
     The localization properties of arterivirus nsp’s are largely based on studies of Vero and other 
cell lines during infection with EAV, the prototypic member of the arterivirus group. During 
EAV infection, both ORF1a and 1b products have been shown to localize predominately to 
replication complexes in the cytoplasm. In this study, we utilized confocal microscopy and 
EGFP labeling to determine the subcellular localization properties of the individual PRRSV 
nsp’s in the absence of infection. The localization of the PRRSV ORF1a products, nsp 1, 2 and 3 
were similar to observations reported for the corresponding EAV proteins (9, 14). For instance, 
PRRSV EGFP-nsp1 accumulated in both the cytoplasm and the nucleus; whereas, nsp2 and 3 
were retained in the cytoplasm (Fig. 4.3B, C and D).  The accumulation of EGFP-nsp1 in the 
nucleus was evident by the co-localization of EGFP with the nuclear stain, TO-PRO-3 (Fig. 
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4.3B). EGFP-labeled nsp4 and 7 localized to the cytoplasm and the nucleus. Since both proteins 
were expressed as intact fusion proteins (Fig. 4.2), it is unlikely that fluorescence in the nucleus 
was the result of the removal and diffusion of free EGFP from the cytoplasm through the nuclear 
pore complex (NPC) and into the cytoplasm. These observations are in contrast to Snijder et al. 
(14) who reported anti-EAV nsp4 and anti-nsp7 staining as predominately cytoplasmic. It should 
be noted that during infection, antibodies specific for EAV nsp4 or 7 would also recognize the 
much larger nsp3-8 polyprotein.  
     The mechanism for the accumulation of GFP-nsp1 (45 kDa), GFP-nsp4 (47 kDa) and GFP-
nsp7 (50 kDa) in the nucleus is unclear.  The molecular sizes for these proteins are near the 50 
kDa cutoff attributed to proteins that can enter the nucleus by passive diffusion through the NPC 
[15]. The intracellular distribution of all three proteins resembled the distribution of the 33 kDa 
EGFP  (Fig. 4.3A), suggesting that nuclear accumulation is the result of passive diffusion 
through the NPC. Another possibility is active transport, which is initiated through an interaction 
between a peptide nuclear localization signal (NLS) on the cargo and an importin receptor 
protein (15). A search for classical NLS motifs using the web-based computer program, PSORT 
(16), showed that only nsp2 and nsp7 possessed potential NLS motifs.  In nsp7, the NLS motif, 
KKKRRR, is located at amino acid 163 of nsp7 or amino acid 2362 in pp1a. A classical NLS 
could participate in the shuttling of nsp7 into the nucleus.  Based on peptide sequence analysis, 
nsp2 contained a cluster of seven classical NLS motifs located between amino acids 821 and 930 
of pp1a. However, since nsp2 is clearly cytoplasmic, the NLS domains are either sterically 
blocked or superceded by cytoplasmic retention signals.  
     ORF1b codes for four proteins, a RNA polymerase protein (RdRp) nsp9; a metal-binding 
protein with helicase activity (M/Hel) nsp10; a NendoU domain-containing protein, nsp11; and a 
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hydrophobic protein of unknown function, nsp12 (5, 6, 7).  All ORF1b proteins are processed via 
the action of SP (nsp4). The complete proteolytic processing of the ORF1b polyprotein is 
essential for EAV replication (17). When tagged with EGFP, PRRSV nsp9 was predominately 
cytoplasmic, with only a small amount of EGFP in the nucleus (Fig. 4.4A). Both EGFP-labeled 
nsp10 and 11 localized to both the cytoplasm and the nucleus (Fig. 4.4B and C). The localization 
pattern for PRRSV EGFP-nsp11 was similar to the diffuse distribution pattern described for 
nsp11 of EAV (18).  Since Westerns showed that EGFP-labeled nsp10 and nsp11 were expressed 
as intact fusion proteins, it is unlikely that the accumulation of fluorescence in the nucleus was a 
consequence of the diffusion of free EGFP into the nucleus. As shown in the Westerns in Fig. 
4.2, EGFP-labeled nsp10 and nsp11 proteins migrated at approximately 75 kDa and 65 kDa, 
respectively. Both fusion proteins are larger than the size of proteins that enter the nucleoplasm 
by passive diffusion through the NPC. A search of peptide sequences failed to identify classical 
NLS motifs. The smallest ORF1b product, nsp12, which was only 53 amino acids or about 40 
kDa when fused to EGFP, was retained in the cytoplasm. 
 
The absence of co-localization of nsp2, 3, 9 with ER-specific antibodies 
     During the replication of EAV in Vero cells, pp1ab-derived proteins assemble into replication 
complexes that co-localize with PDI, an ER resident protein (19).  It is the re-organization and 
recruitment of ER membranes by viral scaffolding proteins, such as nsp2 and 3, that form the 
Double membrane vesicles (DMVs) (4, 8). We studied the co-localization of EGFP-labeled 
PRRSV nsp2 and 3 with antibodies specific for calnexin. Calnexin is an ER-resident protein that 
participates in calcium release and functions as a chaperone in the folding of N-glycosylated 
proteins (20). Confocal microscopy was used to study the distribution of the EGFP tagged nsp’s 
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and AlexaFluor 594-labeled antibodies in the same cells. As shown in representative images in 
Fig. 4.5, there was no co-localization between the cytoplasmic proteins, PRRSV nsp2 and 3, and 
calnexin antibody, which was evident by the absence of yellow color in the merged images in 
Fig. 4.5. All images represented relatively thin, 4.74 µM thick sections through each cell. There 
was also no detectable co-localization between the organelle-specific antibody and the ORF1b 
protein, nsp9 (Fig. 4.5C). 
 
Localization properties of nsp2 -EGFP expressed by a recombinant PRRS virus 
     Using a PRRSV cDNA infectious clone, pCMV-S-P129 (21), we attempted to construct 
recombinant viruses that expressed nsp-GFP fusion proteins. We prepared constructs designed to 
express nsp2-EGFP, nsp3-EGFP and nsp4-EGFP.  Only the nsp2-EGFP virus was viable and 
produced fluorescent cells. Furthermore, when compared to the parent P129 virus, the EGFP-
nsp2 virus replicated to the same levels in MARC-145 cells and in porcine alveolar 
macrophages. EGFP expression was localized in the cytoplasm; often accumulating within the 
perinuclear region of the cell.  The localization properties of nsp2-EGFP, when expressed alone 
or by the EGFP virus were similar.  The results of co-localization studies using antibodies 
against the ER or Golgi or autophagic markers showed no co-localization with EGFP in cells 
infected with the P129-nsp2-EGFP virus (Fig. 4.6A and B, C and D).   
          Along with the non-structural proteins, structural proteins, such as the N protein of EAV, 
also localize to replication complexes (22). Furthermore, confocal microscopy shows co-
localization between anti-N and anti-nsp2 antibodies in EAV-infected Vero cells. However, the 
participation of N in the function of the replication complex is unclear, since the expression of N 
not essential for genome replication or the synthesis of viral subgenomic mRNAs (22).   MARC-
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145 cells infected with the recombinant PRRSV isolate, P129-nsp2-EGFP, were fixed and 
stained with AlexaFluor 594-labeled anti-nucleocapsid mAb, SDOW-17. The distribution of the 
EGFP label was primarily perinuclear and sometimes polarized to one side of the cell, a pattern 
observed for the localization of EAV ORF1a and 1b products (14, 18). The results presented in 
Fig. 4.6E show an example of PRRSV N protein distribution, with localization of N in both the 
nucleus and the cytoplasm.  Nuclear staining localized to a region of the nucleus corresponding 
to the nucleolus (11, 12). The merging of EGFP and N protein images in the same cell showed 
regions of co-localization, which were evident by areas of yellow staining in the merged images.  
These data indicate that similar to EAV, the PRRSV N protein localizes with nsp2 in replication 
complexes.    
 
DISCUSSION 
     How a viral protein functions in the cell during virus replication is related to its location 
within a particular subcellular compartment. In the case of the nidoviruses, both structural and 
non-structural proteins have been shown to localize to the cytoplasm, the site of replication and 
virion assembly and to the nucleus, a mechanism to modify host cell processes. In this study, we 
followed the intracellular distribution properties of nine PRRSV nonstructural proteins tagged 
with EGFP. Even though the proteolytically processed pp1ab gene products of arteriviruses 
assemble as part of a replication complex in the cytoplasm, at least five PRRSV non-structural 
proteins, nsp1α, 4, 7, 10 and 11, showed some accumulation in the nucleus.  Those nsp’s 
possessing transmembrane segments, such as nsp2 and 3, were retained in the cytoplasm.  
     Previous studies describing the distribution of EAV ORF1a and 1b products identified only 
nsp1 as being nuclear (9). The nsp’s of EAV localize to replication complexes in the perinuclear 
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region of the cell.  For the smaller PRRSV nsp products, such as EGFP-labeled nsp1α, 4 and 7, 
the presence of the EGFP-labeled protein in the nucleus can be easily explained by passive 
diffusion from the cytoplasm, through the NPC and then into the nucleoplasm.  Only one 
PRRSV nuclear protein nsp7, possessed a classical NLS motif; however, whether this peptide 
domain functions as a legitimate NLS remains unknown.   The two PRRSV ORF1b proteins that 
localized to the nucleus were nsp10 and 11. Unlike the ORF1a products that localized to the 
nucleus, nsp10 and 11, when tagged with EGFP, exceeded the 50 kDa cutoff size typically 
associated with proteins that can move into the nucleus by passive diffusion. Both proteins lack a 
classical NLS.  Accumulation in the nucleus for these larger proteins could be the result of the 
use of a non-classical NLS or by co-transport with a cellular protein.  
     The role that localization of PRRSV nsp’s to the nucleus might play during virus replication 
is not known. In the case of EAV, nsp1 is essential for subgenomic mRNA synthesis, but is 
dispensable for genome replication (23).  Using a yeast two-hybrid system, (23) showed an 
association between EAV nsp1 and a cellular protein, p100,  a transcription factor. It was 
postulated that EAV nsp1 could be involved in the recruitment of p100 into the cytoplasmic 
replication complexes. Another possibility is that the association between nsp1 and p100 in the 
nucleus is involved in regulating host cell transcription (23). It remains to be determined if 
PRRSV nsp1 associates with p100 or other transcription-related proteins.   In EAV, nsp10 and 
11 are RNA binding proteins involved in viral transcription and genome replication. nsp10 
possesses NTPase and RNA/DNA duplex-unwinding activities (5, 6).  nsp11 contains a NendoU 
domain, which is conserved in all nidoviruses and shares similarities to the XendoU 
endoribonuclease of the Xenopus laevis.  XendoU is a RNA binding protein that participates in 
the processing of nucleolar RNA (7).  Mutagenesis of conserved amino acid residues in the 
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NendoU of EAV affect both genomic and subgenomic RNA synthesis, including mutations that 
were lethal. Interestingly, mutations that inhibited endonuclease activity are non-lethal, but result 
in a reduced plaque size (24). For EAV, the ORF1b products are perinuclear (18). However, 
antisera against a peptide in nsp11 of EAV recognizes the appropriate 26 kDa product, and  
immunofluorescence staining of infected cells reveals a nonspecific distribution pattern, with 
staining throughout the cell.  It is tempting to speculate that PRRSV transcription regulatory 
proteins, such nsp10 and 11, could be transiently shuttled into the nucleus and influence the 
transcription and processing of host cell RNAs.   
     Positive polarity, single-stranded RNA viruses typically incorporate cell membranes derived 
from organelles into the formation of replication complexes. The replication complexes are the 
factories that produce viral nucleic acids, including viral mRNAs, genomes and anti-genomes.  
For the nidoviruses, including the coronaviruses and arteriviruses, replication complexes are 
formed in association with double membrane vesicles (DMVs). In the case of the arteriviruses, 
the scaffolding proteins nsp2 and 3 are sufficient to form DMV-like structures (4).  Scaffolding 
proteins also anchor and position the other the nsp components, including the RdRP and helicase 
within the replication complex. At least one arterivirus structural protein, N, is also associated 
with the replication complex; however, N is not required for viral RNA synthesis (22). 
Replication culminates in the assembly of virions and internal budding from the ER/Golgi 
region.  For RNA viruses in general, there are several sources of membranes that are recruited 
into the replication complexes, including the ER, lysosomes, endosomes, Golgi, autophagosomes 
and mitochondria (25, 26, 27, 28, 29, 30). In the case of the nidoviruses, immunofluorescence 
staining with nsp-specific antibodies shows that replicase subunits localize to the perinuclear 
region of the cell.  For coronaviruses, such as MHV, the DMVs are associated with membranes 
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derived from autophagic vacuoles (28).  In contrast, for the arterivirus, EAV, the DMVs are 
derived from the ER (8).  Recently, Snijder et al showed that the DMV structures formed during 
SARS-CoV infection of Vero cells are not associated with autophagic vacuolar proteins, but with 
membranes derived from the ER.  Therefore, within the nidoviruses, there appears to some 
flexibility in the types of membranes that can be incorporated into replication complexes. The 
results from this study showed that none of the EGFP-nsp products studied colocalized with 
either Golgi and ER or autophagic markers. One possibility is that the EGFP-labeled proteins 
behave differently from nsp’s produced during virus infection.  However, the incorporation of 
EGFP-nsp2 into an infections clone showed that GFP fluorescence was able to co-localize with 
the N protein, but still failed to co-localize with the ER marker, calnexin and PDI, the Golgi and 
autophagic marker, LAMP-1. Again, the possibility exists that EGFP-labeled nsp2 may behave 
differently from the wild type nsp2. Another possibility is that similar to the coronaviruses, there 
maybe differences within the arteriviruses in the types of membranes incorporated into DMVs.  
It remains to be determined the source of the membranes utilized by the PRRSV replication 
complex.  
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Table 4.1. Sequence of primers used to amplify nonstructural proteins of PRRSV 
Primer Sequence1 Primer Sequence1
Nsp1  nsp7  
For 5’-CTCGAGATGTCTGGGATACTTGATCGG For 5’-CTCGAGTCTCTGACTGGTGCCCTCGC 
Rev 5’-GAATTCTAAGCCGTACCACTTGTGACTGCCAA Rev 5’-GGATCCGCTTCCCATTGGACTCTTCC 
Nsp2  nsp8  
For 5’-GAGCTCGCTGGAAAGAGAGCAAGAAAA For 5’-CTCGAGGCAAAGCTTTCTGTGGAGC 
Rev 5’-GGATCCGCCCAGTAACCTGCCAAGAATGG Rev 5’-GGATCCTAGCAGTTTAAACACTGCTC 
Nsp2*2  nsp9  
For 5’-GAGCTCATGGCTGGGAGGAGAGCAAGG For 5’-CTCGAGATGGGAGCAGTGTTTAAACTGC 
Rev 5’-GGATCCTAAGGTCCCACATGCGGGAAAGCC Rev 5’-GGATCCTAACTCATAATTGGATCTGAGTTT 
Nsp3  nsp10  
For 5’-CTCGAGGGGGCACGTTGCATCTGGCA For 5’-CTCGAGATGGGGAAGAAGTCGAGAGTGT 
Rev 5’-GGATCCCTCAAGAAGAGACCCAAGCTG Rev 5’-GGATCCTAATTCTAGATCAGCACAAATGGC 
Nsp4  nsp11  
For 5’-CTCGAGATGGGTGCTTTCAGAACTCGAAAG For 5’-CTCGAGATGGGTACGAGCTCTCCGCTCC 
Rev 5’-GGATCCTAATTCCAGTTCAGGTTTGGCAGCAA Rev 5’-GGATCCTAATTCAAGTTGGAAATAGGCTGT 
nsp5  nsp12  
For 5’ CTCGAGGGGGGCCTCTCCACCGTCCA For 5’-CTCGAGGGTCGCTATTTCACCTGGTA              
Rev 5’ GGATCCCCCTCGGCAAAGTATCGCAAGA    Rev 5-’GGATCCTCAATTCAGGCCTAAAGTTG     
 
1Restriction enzyme recognition sites added to the primers used for cDNA synthesis are underlined. Primer 
sequence are based on the SD23983 PRRSV strain of North American PRRSV. The restrictions used for cloning 
were Sac 1 (GAGCTC), Xho 1(CTCGAG), Eco R1 (GAATTC) and Bam H1 (GGATCC). 
2Truncated nsp2. 
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Fig. 4.1.  Processing of pp1a and pp1ab proteins of PRRSV.   The cleavage sites and products are 
identified based on the analysis of EAV and PRRSV processing of ORF1a and 1b gene products. 
PCB, papain-like cysteine protease; CP, chymotrypsin-like protease; HD, hydrophobic domain; 
SP, serine protease, RdRp, RNA-dependent RNA polymerase; M/Hel, metal binding/helicase; 
NendoU, NendoU domain. 
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Fig. 4.2. Western blot of PRRSV EGFP-nsp fusion products.  Plasmid constructs were prepared 
that expressed EGFP fused to the N-terminal end of each nsp.  Fusion constructs were expressed 
in Vero cells and detected in immunoblots using a polyclonal anti-GFP antibody.  nsp2* is a 
truncated fusion protein with 280 amino acids removed from the C-terminal end of nsp2. The 
arrow identifies a smaller product from cells expressing EGFP-nsp2*.    
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Fig. 4.3. Confocal microscopy of ORF1a EGFP-nsp products expressed in Vero cells. Cells were 
transfected with plasmid constructs expressing ORF1a nsp cDNA products and viewed the next 
day. Cells were counterstained with the nuclear stain, TO-PRO-3 (blue). Each image represents a 
4.74 µM thick slice. In order from right to left: EGFP expression, TO-PRO-3 staining and 
merged image.   
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Fig. 4.4. Confocal microscopy of ORF1b EGFP-nsp products expressed in Vero cells. Cells were 
transfected with plasmid constructs expressing ORF1b nsp cDNA products and viewed the next 
day. Cells were counterstained with the nuclear stain, TO-PRO-3 (blue). Each image represents a 
4.74 µM thick slice. In order from left to right: EGFP expression, TO-PRO-3 staining and 
merged image.   
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Fig. 4.5.  Colocalization of anti-calnexin and GFP. Confocal microscopic images of cells 
transfected with EGFP-nsp plasmids and stained with the anti-calnexin antibody, mAb AF18. 
The mouse mAb was detected with AlexaFluor 594-labeled anti-mouse (red color).  Each image 
represents a 4.74 µM thick slice. In order from left to right: EGFP expression, AlexaFluor 
staining and the merged image of the same cells.   
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Fig. 4.6. Distribution of anti-calnexin, anti-PDI, anti-Golgi, anti-autophagic marker (LAMP-1), 
and anti-PRRSV N protein staining in MARC-145 cells infected with P129-nsp2-EGFP. 
Confocal microscopic images showing co-localization of nsp2-EGFP with anti-calnexin (mAb 
AF18), anti-PDI (mAb 1D3), anti-Golgi (mAb 371-4) and anti-LAMP-1 (mAb H4A3), anti-
nucleocapsid (mAb). Cells were infected with PRRSV isolate, P129-nsp2-EGFP, fixed 
approximately 48 hr later and stained with antibody. Mouse antibodies were detected with 
AlexaFluor 594-labeled anti-mouse (red color).  Each image represents a 4.74 µM thick slice. In 
order from left to right: EGFP expression, AlexaFluor staining and the merged image of the same 
cells.   
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CONCLUSION AND FUTURE PROSPECTS 
    Despite the tremendous efforts invested in controlling PRRSV infections, the virus continues 
to plague the swine industry and damage pig production worldwide. PRRSV infects immune 
cells and modifies the normal host immune function. The host response to infection is poor and 
the virus persists in infected pigs for prolonged periods of time. Genetic and antigenic variants 
rapidly arise, and an effective and safe vaccine is still unavailable. The recent development of 
reverse genetics systems for PRRSV allows us to engineer the viral genome and to create 
genetically defined mutant viruses. This study focused on analysis of the multifunctional 
nonstructural protein (nsp2) that could be a site of foreign gene expression. The usefulness as a 
viral vector can enlighten an effective gene therapy road against harmful animal viral diseases. 
Also, our marker PRRSV virus without relatively conserved 131 amino acid region can pave the 
way for DIVA vaccine for the first time in the PRRSV research field. For better vaccine strategy, 
the possibility of converting live vaccine into virulent form and recombination among vaccine 
strains and field isolates can’t be excluded.  
The next major questions selected, coupled with the capacity to isolate large mutants in each of 
the PRRSV nonstructural proteins (nsps), could include. (1) Are any nsps beside nsp2 
nonessential? (2) Is the gene order of nsps critical? (3) Are nsps interchangeable between Type 1 
and 2 PRRSV? (4) How do the replication complexes form on membranes? (5) What nsp 
complexes regulate discontinuous transcription and synthesis of genome-length and subgenomic-
length mRNAs and negative-strand RNAs? (6) What are the structure-function relationships 
within and between various nsps? (7) What are the functions of each of the nsps, and how do 
they influence the pathogenesis of PRRSV? 
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Using the available infectious PRRSV cDNA clones, a specific solution against fundamental 
questions of PRRSV genetics will be suggested sooner or later. This information will 
undoubtedly enable a second generation of safe and effective PRRSV vaccine. 
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